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1.0. INTRODUCTION  
                     The infection of a wound can be defined as the invasion of organisms 
through tissues following a breakdown of local and systemic host defences, leading to 
cellulitis, lymphangitis, abscess and bacteraemia. Infections of surgical wounds are 
called as surgical site infections (SSIs).
1 
                   SSIs are defined as infections occurring within 30 days after a surgery or 
within one year if an implant is left in place after the procedure and affecting either 
the incision or deep tissue at the operation site
2
. 
                  According to the National Nosocomial Infection Surveillance program 
(NNIS), it is classified into superficial, deep, organ/space infections
3
.   
                  Source of SSIs include the patient‘s own normal flora, organisms present 
in the hospital environment that are introduced into the patient by medical procedures, 
specific underlying disease, trauma or burns which may cause a mucosal or skin 
surface interruption.
4
 
                  SSIs are serious operative complications that occur in approximately 2% of 
surgical procedures and account for 20% of health care-associated infections. Many 
studies reported that SSIs rank third among common nosocomial infection next only 
tourinary tract and respiratory tract infections.
2,6
 
                 Recent studies reported that SSI rate ranges from 19.4% to 36.5% 
7
all over 
the world, whereas in India it ranges from 3% to 12%.
8,9
 
                    SSI remains a common and widespread problem that contributes to 
significant morbidity and mortality, prolongs hospital stay and consequently 
increasing health care cost 
2 
 
                   Factors which promote SSIs include length of hospital stay, Obesity, 
Diabetes mellitus, smoking etc..The development of a post operative wound infection 
depends on the complex interplay of many factors. Most postoperative wounds are 
endogenous. Exogenous infections are mainly acquired from the nose or skin flora of 
the operating team and transmitted through the hands of the surgeon or improper 
operation theatre steriliation
10
which includes pre operative, intra operative and post 
operative care 
                 Some significant factors that can influence the incidence of subsequent 
infection are surgical techniques, skin preparation, timing, method of wound closure 
and antibiotic prophylaxis after certain types of surgery. Also many other factors have 
been identified as having an effect on the potential for infection and these should be 
considered by the healthcare professionals before, during and after surgery.
11 
Table no.1. Common causes of SSIs: 
Gram positive organisms Gram negative organisms 
Staphylococcus aureus 
CONS 
Enterococci 
Eschericia coli 
Klebsiella spp 
Proteus spp 
Enterobacter spp 
Pseudomonas spp 
Acinetobacter spp 
                The resistance offered by a microbe to antimicrobial agent that is used in the 
prevention or treatment of infections is called antimicrobial resistance.
12
Beta -lactams 
are the most widely used antibiotics for treatment of postoperative woundsdue to their 
broad spectrum of activity, safety profile and proven clinical efficacy.
13
There are 
3 
 
different mechanisms which cause resistance to beta lactams namely a reduction in the 
affinity of the drug targets (penicillin binding proteins) via amino-acid substitution, a 
phenomenon occurring in both gram positive and gram negative bacteria. Gram 
negative species, alteration in outer-membrane permeability that prevents passage to 
the beta lactams and in both Gram-positive and Gram-negative bacteria, the 
production of beta lactamase that inactivate the drug through hydrolysis of the beta 
lactam ring. Hence widespread use of these groups of antibiotics has lead to 
emergence and rapid spread of resistance.
14
 
                       Among the members of the Enterobacteriaceae family, resistance to β 
lactams has been reported to be associated with ESBL and Amp C β- lactamase.15 
ESBL producing organisms hydrolyze oxyamino β- lactams like Cefotaxime, 
Ceftriaxone, Ceftazidime and Monobactams but have no effect on Cephamycins, 
Carbapenems and related compounds.
16 
                      Production of β- lactamase is frequently plasmid encoded and bears 
clinical significance. Plasmids responsible for ESBL and Amp C β- lactamase 
production frequently carry genes encoding resistance to other drugs also and 
therefore antibiotic options in the treatment of β- lactamase producing organisms are 
extremely limited.
17 
                      Data from last few decades show an increasing resistance for drugs that 
were considered as the first line of treatment for post-operative wound 
infections.
18
The most frequent co-resistances which are found in ESBL producing 
organisms are amino glycosides, tetracyclines, chloramphenicol, trimethoprim-
sulfamethoxazole and fluoroquinolones. To stress precise empirical therapy, antibiotic 
4 
 
policies should be implemented to reduce hospital length of stay, morbidity and 
expenditure per day in the hospital.
19 
                      The carbapenemases are betalactamases that are capable of inactivating 
or hydrolyzing the carbapenem group of betalactam antibiotics. This is the main cause 
of carbapenem resistance in gram negative bacilli. Hyperproduction of enzymes called 
Amp C betalactamases can also result in resistance to carbepenem.
20
 
                     The isolates which showed resistance to at least three or more than three 
groups of antibiotics were considered as multi drug resistant (MDR). 
                      The prevalence of antimicrobial resistance pattern may vary between 
geographical areas. However, the publications available on the susceptibility pattern 
of bacterial isolates causing SSI and ESBL prevalence in South India are minimal. 
Hence, the present study is under taken at Trichy SRM Medical College and Research 
Centre situated at Irungalur, Trichy in India, which is a tertiary care hospital serving 
rural population mostly, prevalent bacteria and their susceptibility pattern, risk factors 
in order to facilitate effective management of SSI. 
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                                            2.0. AIMS AND OBJECTIVES 
1. To find out the prevalence of SSI in this hospital. 
2. To elicit the association between bacterial isolates and anatomical site of 
infection. 
3. To identify the probable risk factors for development of surgical site infections 
4. To isolate and identify aerobic pathogenic bacteria from surgical site infections 
(SSI). 
5. To determine the antimicrobial sensitivity pattern of pathogens. 
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                              3.0. REVIEW OF LITERATURE 
                     Surgical site infection (SSI) has always been one of the major 
complications in surgical patients. It has been first mentioned even around BC. They 
have been described and documented since ancient times (4000-5000 years) and 
considered as one of the important nosocomial infections worldwide. 
                   In 1846, Ignaz Semmelweis noticed that the mortality from puerperal 
fever was much higher in teaching ward. He also made interesting observation that 
women who delivered before arrival in the teaching ward had a negligible mortality 
rate. The tragic death of a colleague due to overwhelming infection after a knife 
scratch received during an autopsy of awomen who died of puerperal sepsis led Ignaz 
to observe that pathologic changes in his friend were identical. Then, he hypothesized 
that puerperal fever was caused by putrid material transmitted from patients by 
carriage on examining fingers of medical students and physicians who frequently went 
from autopsy room to the wards. He posted a notice on the door to the ward requesting 
all caregivers to rinse their hands thoroughly in chlorine water before entering the 
area. This simple intervention reduced mortality of puerperal fever to 1.5%.
21 
                        In 19
th
 century, Louis pauster proposed germ theory. His work in 
humans followed experiments identifying infectious agent in silk worms. He stated 
that contagious diseases are caused by specific microbes and that microbes are foreign 
to the host. Using this principle, he developed the techniques of sterilization. 
7 
 
                In 1904, William Osler discovered the first cytokines which began to allow 
insight into organism‘s response to infection, and led to the explosion in our 
understanding of host inflammatory response.
22 
The word ‗Hospitalism‘ was introduced by Sir James Simpson to describe what we 
now call hospital acquired surgical site infections. The following table describes the 
Historical background of surgical site infections. 
Table no.2: Historical Perspectives of Surgical site infections:
23 
S.No Contributors  Period  Contributions 
1 Hippocrates BC 460 – 375 Used wine & vinegar for simple wound 
irrigation  
2 Galen 130-200 Recognized localization of infection 
(suppuration) in wounds inflicted in the 
gladiatorial arena often heralded 
recovery, particularly after drainage. 
3 Theodoric of Cervia 
Ambroise Pare 
Guy de Chaulic 
1210-
98?1298-1368 
1510-90 
Observed clean wounds, closure of 
wounds favours healing without 
localization/infection/suppuration 
4 Ignac Semmelweis 1818-65 Introduced hand washing technique & 
proved reduction of puerperal sepsis 
(10% to 2%) by simple hand washing 
steps in between surgeries 
8 
 
5 Joseph Lister 1827-1912 Pioneer of antiseptic surgery. 
Introduced carbolic acid to clean 
wounds and for sterilizing surgical 
instruments. 
6 Alexander Fleming 1881-1955 Introduced chemotherapeutic agents 
like sulphonamides and penicillin 
 
 
3.1. CLASSIFICATION OF SURGICAL WOUNDS: 
                     The risk of infection varies by type of surgical incision site. Invasive 
procedures that penetrate bacteria-laden body sites, especially the bowel, are more 
prone to infection. The theoretical degree of contamination, proposed by the National 
Research Council(USA) over 40 years ago, relates well to infection rates.
23
 The 
traditional wound classification system designed by the CDC stratifies the increased 
likelihood and extent of bacterial contamination during the surgical procedure into 
four separate classes of procedures
24 
 Based on degree of microbial contamination.
25
 
 
 
 
 
 
Clean wound:   
Elective, not emergency, non-traumatic, primarily closed; no signs of acute 
inflammation;  
 Clean wound 
 Clean-contaminated wound 
 Contaminated wound 
 Dirtywound 
 
9 
 
No break in technique;  
Respiratory, gastrointestinal, biliary and genitourinary tracts not entered  
Clean-contaminated:  A number of studies carried out in India indicate an overall 
SSI rate of 4.04 to 30% for clean surgeries and 10.06 to 45% for clean-contaminated 
surgeries.
 26, 27
 
Emergency case that is otherwise clean  
Elective opening of respiratory, gastrointestinal, biliary or genitourinary tract with 
minimal spillage (e.g. appendectomy) not encountering infected urine or bile  
Minor break in technique.  
Contaminated:  
Acute, non-purulent inflammation  
Gross spillage from gastrointestinal tract and entry into biliary or genitourinary tract in 
the presence of infected bile or urine. 
Major break in technique  
Penetrating trauma of less than 4 hours  
Chronic open wounds to be grafted or covered  
Dirty or Infected:  
Purulent inflammation of the wound (e.g. abscess);  
Preoperative perforation of respiratory, gastrointestinal, biliary or genitourinary tract; 
Penetrating trauma of 4hours.
28
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3.2. CLASSIFICATION OF SURGICAL SITE INFECTION: 
The CDC Guideline for prevention of surgical site infection, published in 1999 
defining an SSI 
 Superficial incisional  SSI 
 Deep incisional  SSI 
 Organ/ Space SSI 
 
Figure no. 1: Cross section of abdominal wall depicting CDC classification of 
SSIs
2
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Superficial incisional SSI: 
Infection occurs within 30 days of surgery and infection involves only skin or 
subcutaneous tissue of the incision and patient must present with atleast one of the 
following criteria: 
 Purulent discharge with or without laboratory confirmation.  
 Organism isolated from aseptically obtained culture of fluid or tissue from the 
superficial incision.  
 At least one of the following signs of inflammation: pain or tenderness, 
localized swelling, redness or heat and superficial incision deliberately opened 
by a surgeon unless incision is culture negative.  
 Diagnosis of superficial incisional SSI by the surgeon.  
 Excluding stitch abscess, infected burn wounds. 
Deep incisional SSI: 
Infection involves incision site that extend into the fascial and muscle layers and 
patient must present with atleast one of the followingcriteria: 
 Purulent discharge  
 Deep incision spontaneously dehisces or deliberately opened by a surgeon and 
is culture positive or not cultured when the patient has any of the signs and 
symptoms of inflammation. 
 Evidence of infection by direct examination, during reoperation, or by 
histopathological and radiological examination. 
12 
 
 Diagnosis of deep incisional SSI by the surgeon. 
Organ/ Space SSI: 
Infection involves any part of anatomy (organs / spaces) other than the incision. 
 Purulent discharge from drain that is placed through a stab wound into organ/ 
space. 
 Evidence of infection by direct examination, during reoperation, or by 
laboratory confirmation, histopathological and radiological examination. 
 Diagnosis of Organ/ Space SSI by the surgeon or attending physician.2 
3.3. PATHOPHYSIOLOGY:
29 
Normally entry of microorganism is prevented by the 
intact epithelial surfaces. Apart from this there are also other protective mechanism in 
the host namely  
➢Cellular: Phagocytic cells, macrophages, polymorphonuclear cells and killer 
lymphocytes.  
➢Humoral: Antibodies against the microorganisms, complement and opsonins 
➢Chemical: Acidic pH of the stomach  
Reduced host response to infection may be due to:  
➢ Metabolic: Malnutrition, Diabetes mellitus, Uremia, Jaundice. 
➢ Cancer, Acquired Immune Deficiency Syndrome (AIDS)  
➢ Iatrogenic: Chemotherapy, radiotherapy and steroids.  
Source: Endogenous> exogenous origin 
 
13 
 
3.4. Pathogenesis of surgical site infections: 
 
 
3.5. Risk factors of SSI:  
                        Kowli et al. (1985) found an infection rate of 17.4% when preoperative 
stay was 0-7 days, and an infection rate of 71.4% with a preoperative stay of more 
than 21 days.
12
Nichols et al (1997) in his study on Prolonged postoperative 
hospitalization, which is a major concern of most of the hospitals, has been evident in 
patients developing surgical site infection.
30
Anvikar et al. (1999) established that 
preoperative hospital stay predisposed an individual to 1.76% risk of nosocomial 
infection. With an increase in preoperative stay, the risk increased proportionally. A 
preoperative stay of one week increased the risk rate to 5% 
31
.  
Contamination
•exogenous/ endogenous/hematogenous 
Proliferation of bacteria
Induce inflammation,signs & symptoms 
Identified or unidentified
Self resolving/ resolve by treatment/ sepsis & death
14 
 
               A mean postoperative stay in patients who developed infection was almost 
three times as compared to patients who did not develop SSI. The results indicated 
that 12% of patients undergoing surgery developed SSI.
31 
               In 1988 Lilienfeld et al published reports have demonstrated that patients 
with diabetes mellitus and obesity are more susceptible to wound infection because of 
impaired neutrophil chemotaxis and phagocytosis. 
               Malnutrition has long been identified as a risk for nosocomial infections, 
including SSI, among patients undergoing any type of surgery.
32
 
              Clip the hair immediately before an operation also has been shows a lower 
risk of SSI than shaving or clipping the night before an operation (SSI rates 
immediately before = 1.8% vs night before = 4.0%). Dessie et al reported emergency 
surgeries more prone to SSIs. Dirty and contaminated surgeries are more likely to 
develop SSIs.
32a,b,c,e 
            The risk for developing SSI is a complex interaction between the patient, the 
procedure and environmental factors which have been listed in the boxes given below.
 
33,34,35 
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Environment factors: 
 
 
 
 
In 1964,  Altemeir and Culbertson conceptualized the pathogenic relationship, key 
factors of SSIs and also stated that risk of SSIis directly proportional to the microbial 
Host related factors: 
 Age 
 Obesity  
 Severity of disease 
 ASA score(American society of 
anesthesiologist) 
 Nasal carriers of MRSA 
 Remote infection  
 Duration of preoperative 
hospitalization 
 Malnutrition  
 Diabetes mellitus 
 Malignancy 
 Immunosuppressive therapy  
 
Procedure related factors: 
 Type of procedure 
 Preoperative hair removal 
 Antibiotic prophylaxis 
 Duration of surgery 
 Skin disinfection 
 Trauma to tissue  
 Foreign materials 
 Drains  
 Blood transfusion 
 Emergency surgery  
 
 Improper post-operative wound care 
 Length of post-operative stay 
 Uncontrolled blood glucose  
 Inadequate Hand hygiene of HCWs            
 
16 
 
contamination of the operative wound and to virulence of the microorganism and 
inversely proportional to the integrity and resistance of the host defenses. 
   Risk of SSI= Dose of bacterial contamination x Virulence of microorganism 
                                        Resistance of patient defence 
As per American Society of Anesthesiologists (ASA), SSI has been scored based on 
preoperative physical status of the patient and shown in Table 2 
Table no.3: American Society of Anesthesiologists score based on physical status 
ASA Score  Patient‘s preoperative physical status 
1 Normally healthy patient 
2 Patient with mild systemic disease 
3 Patient with severe systemic disease that is not incapacitation 
4 Patient with incapacitation systemic disease that is constant threat to life  
5 Moribund patient who is not expected to survive 24hrs with or without 
surgery  
 
              ASA score is an index to assess overall physical status of patient before 
operation ranging from 1 to 5. It has been shown highly predictive for development of 
SSI.
36
 
                CDC has developed National Nosocomial Infections Surveillance System 
(NNIS) risk index in the year 1991
37
as an improvement over SENIC (Study on 
17 
 
Efficacy of Nosocomial Infection Control) risk index which ranges from 0 to 3 points 
and is defined by three independent and equally weighted variables.  
One point is scored for each of the following if present:  
• ASA physical status score >2 
• Either contaminated or dirty/infected wound classification 
• Length of operation > T hours (where T is approximate 75th  percentile of duration 
of the specific operation being performed.
38
 
3.6. Causative Agents:
22 
Table no.4: Causative agents of SSIs: 
Gram positive cocci 
Staphylococcus aureus 
Staphylococcus epidermidis 
Streptococcus pyogenes 
Streptococcus pneumoniae 
Enterococcus feacalis, E. faecium 
Gram negative bacilli 
Escherichia coli 
Hemophilus influenzae 
Klebsiella pneumonia 
Proteus mirabilis 
Enterobacter aerogenes, e. cloacae 
Serratia marcescena 
Acinetobacter spp 
Citrobacter freundii 
Other bacteria  
Mycobacterium spp 
Nocardia asteroids 
Legionella spp 
Listeria monocytogenes 
Fungi 
Candida spp.  
Cryptococcus spp 
Blastomyces dermatitidis 
Aspergillus spp 
Coccidioides immitis 
Mucor/rhizopus 
Viruses 
Cytomegalovirus 
18 
 
Pseudomonas aeroginosa 
Xanthomonas maltophilia 
Anaerobes  
Bacteroids spp.  
Fusobacterium spp.  
Peptostreptococcus 
Clostridium spp 
Epstein –Barr virus 
Hepatitis A,B,C 
Herpes simplex virus 
HIV 
Varicella zoster virus 
 
 
 
 
 
 
 
 
Figure no.2: Common pathogens causing 
SSIs33,34,35
Staphylococcus aureus
CONS
Enterococcus
E.coli
Pseudomonas
Enterobacter
Klebsiella pneumoniae
Candida spp
Klebsiella oxytoca
19 
 
3.7. Historical Aspects of antibiotic prophylaxis: 
                     Experimental studies published during the early 1960s helped clarify 
many of these problems and resulted in a more scientifically accurate approach to 
antimicrobial prophylaxis. Most important was the report by Burke 
39
, which 
demonstrated the crucial relationship between timing of antibiotic administration and 
its prophylactic efficacy. His experimental studies showed that to greatly reduce 
experimental skin infection produced by penicillin-sensitive S. aureus, the penicillin 
had to be in the skin shortly before or at the time of bacterial exposure. This study and 
others fostered the attitude that to prevent subsequent infection the antibiotic must be 
in the tissues before or at the time of bacterial contamination. This important change 
in strategy helped correct the common error of first administering the prophylactic 
antibiotic in the recovery room. 
                   As early as 1964, Bernard and Cole
40
 reported on the successful use of 
prophylactic antibiotics in a randomized, prospective, placebo-controlled clinical 
study of abdominal operations on the gastrointestinal tract. The success of antibiotic 
prophylaxis noted in this early study was clearly due to the authors' appropriate patient 
selection and wise choice of available agents, as well as the timing of administration.  
               Further advances in understanding of antibiotic prophylaxis in abdominal 
surgery occurred in the 1970s. During this decade, the qualitative and quantitative 
nature of the endogenous gastrointestinal flora in health and disease was appropriately 
defined 
41
. Many prospective, blinded clinical studies in the 1980s and 1990s 
prompted definitive recommendations concerning the proper approaches to antibiotic 
prophylaxis in surgeryand shown in table no.5. 
20 
 
3.8. Table no.5: Antibiotic prophylaxis for surgical procedure
42,33 
Surgical procedures Antibiotics  
Cardiac surgery Cefuroxime 1.5g 8 hourly 
Neurosurgery  Cefuroxime 1.5g single dose 
Head and Neck Cefuroxime 1.5g and metronidazole 
500mg 8 h(single dose) involving 
mucous, and upto 3 doses if membrane 
and deep tissue involved 
Biliary tract surgery Cefuroxime 1.5g single dose 
Endoscopic retrograde 
cholangiopancreatography 
Cefuroxime 1.5g single dose 
Gastroduodenal Cefuroxime 1.5g single dose 
Appendectomy  Cefuroxime 1.5g/ gentamycin 2-3mg/kg 
and metronidazole 500mg (single dose) 
Colorectal surgery Cefuroxime 1.5g/ gentamycin 2-3mg/kg 
and metronidazole 500mg (single dose) 
Orthopaedic surgery Cefuroxime 1.5g single dose 
Lower limb amputation Benzylpenicillin 2mega units IV 6 h; 
metronidazole /clindamycin for patient 
allergic to penicillin 
All antibiotic should be given for 24 h 
duration 
Peripheral vascular surgery Cefuroxime 1.5g 8 hourly (3 doses) 
Urological surgery IV antibiotic depends upon urine 
sensitivity report. In emergency condition 
gentamycin 2-3mg/kg 
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Hysterectomy  Cefuroxime 1.5g and metronidazole 
500mg or amoxiclav 1.2g alone(single 
dose) 
Caesarean section Cefuroxime 1.5g  or amoxiclav 1.2g IV 
after umbilical cord is clamped (single ) 
 
3.9. Prevalence of SSIs: 
                    It is estimated that 234 million major surgical procedures are performed 
annually worldwide.
43
 Among all types of Health care associated infections, SSI 
varies from 2.5% to 41.9% all over the world
44,45
. They are associated with longer 
post-operative hospital stays, additional surgical procedures, treatment in intensive 
care units and higher mortality.
46
Many studies reported that it varies from hospital to 
hospital based on infection control measures and antibiotic policy. One review study 
reported that SSI develops around 1 in 20 surgical patients in hospitals
47
 
                Suchithra et al observed that the prevalence of SSIs was 12%; and the 
common etiologic agents are gram-positive organisms like Staphylococcus aureus and 
Enterococcus spp and gram-negative organisms are Pseudomonas aeruginosa, 
Escherchia coli and Klebsiella spp their results are consistent with various other 
literature reports indicating that Staphylococcus aureus was the commonest isolate 
from postoperative wound infection. E. faecalis was seen in 33.3% of surgical site 
infections. Also among the gram-negative bacilli, the predominant isolate was P. 
aeruginosa (24.4%), followed by E. coli (7.4%) and Klebsiella spp. (1.4%). 
48
CDC 
reported a mortality rate of  3%,Weigelt et al reported a total mortality rate of 0.95% 
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for SSIs.
49
Mortality rate of appendectomy is 0.7% and 2.4% in patients without and 
with perforation
50 
                    The modern surgeon cannot escape the responsibility of dealing with 
infections and when dealing with them, should have knowledge of the appropriate use 
of aseptic and antiseptic technique, proper use of prophylactic and therapeutic 
antibiotics and adequate monitoring and support with novel surgical and 
pharmacological modalities, as well as nonpharmacological aids
50
. 
3.10. Antimicrobial Resistance in surgical site infections 
                  Antibiotic era started with discovery of penicillin by Alexander Fleming in 
1928 
58
. Use of Penicillin started in 1941. Emergence of penicillin resistance is 
identified in Staphylococcus aureus due to plasmid encoded β-lactamase. First 
plasmid mediated β-lactamase in gram negative organisms- TEM-1 was described in 
early 1960‘s58. It was first isolated in Escherichia coli from a patient Temoniera in 
Greece and the gene responsible for it was named after him. It spread to other genera 
soon. Evolution of drug resistance is shown in table no.6 given below 
Table no.6: Evolution of drug resistance  
Year  Event (Antimicrobial resistance)  
1937  Sulfonamides introduced for treatment
52 
1940  Penicillin came into clinical use
53
 
1940  First evidence of betalactamases (Penicillinase) demonstrated in 
E.coli by Abraham and Chain
53
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1940  Tetracycline came into clinical use
54 
1953  First tetracycline resistance was reported in Shigella dysentria
54 
1970s  Plasmid mediated β-lactamases assumed importance in 
Enterobacteriaceae and other gram negative bacteria
54
 
1972  First epidemic of Chloramphenicol resistant Salmonella in 
Kerala reported by Paniker et al.
55
 
1989  MDR S.Typhi outbreaks resistant to Chloramphenicol, 
Ampicillin, Trimethoprim, Streptomycin, Tetracycline and 
Sulfonamides were reported in India and Pakistan
55
 
1992  S.Typhi resistant to Ciprofloxacin was first reported in UK.
55
 
1970-80s  Development of broad spectrum Cephalosporins, Cephamycins, 
Monobactams and Carbapenems
53 
1990  Inducible chromosomally mediated β-lactamases among gram 
negative bacteria
53
 
 
Beta lactamases: 
               Enzymes which inactivate betalactam antibiotics by hydrolysing the nitrogen 
carbonyl bond in their betalactam ring are collectively known as betalactamases. They 
are members of a super family of active site serine proteases and act by cleaving an 
amide bond of beta- lactam ring to form an acyl-enzyme complex. They can be 
plasmid mediated or chromosomal .These β-lactamases are secreted as exozymes in 
gram positive bacteria and within the periplasmic space in bacteria that are gram 
negative. More than 170 enzymes of this kind has been discovered 
56
.  
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Methicillin resistant Staphylococcus aureus (MRSA): 
             Methicillin was the first penicillinase resistant penicillin and has been widely 
used in testing susceptibility of S. aureus to penicillinase resistant β-lactam agents. 
Hence, despite the fact that methicillin is no longer available and oxacillin and 
cefoxitin have replaced it for susceptibility testing, resistant strains are commonly 
known as MRSA.  
             MRSA strains are a continuing and increasing problem in healthcare settings, 
with outbreaks now occurring in the community. Screening for MRSA provides a 
means of identifying patients and staff who may be at risk of infection and/or involved 
in transmission of the organism. 
             MRSA were first described in the 1960s 
67
. During the late 1970s and early 
1980s, strains of S. aureus resistant to multiple antibiotics including methicillin and 
gentamicin were increasingly responsible for outbreaks of hospital infection 
worldwide and several clonal types have shown extensive international spread 
68,69,70
 
In England and Wales, the spread of MRSA was well controlled until the 1990s. 
Between 1989 and 1991 only 1.6% of S. aureus bacteraemia isolates were methicillin 
resistant 
71
. However, methicillin resistance rates increased steadily throughout the 
1990s, there were also significant increases in the percentages of isolates resistant to 
erythromycin, clindamycin, ciprofloxacin, gentamicin, trimethoprim and rifampicin
72
. 
MRSA reached in excess of 40% in several regions in 2001 which triggered the 
introduction of mandatory surveillance of MRSA bacteraemia
73
. In 2005, trusts were 
tasked with reducing the number of cases of MRSA and since that time cases have 
fallen
74,75 
Studies have shown that the majority of patients from whom MRSA strains 
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are isolated are colonised rather than infected with the organism 
76
. Factors 
predisposing to superficial colonisation include procedures involving ―hands on‖ care 
especially in acute surgical, renal dialysis and critical care units 
77
. The risk of 
colonisation resulting in infection is increased in the presence of any breach in the 
skin, such as surgical wounds and devices penetrating the skin, for example prostheses 
and catheters, which provide a portal of entry for bacteria 
77
. MRSA and MSSA are 
similar in virulence and this is often connected to mobile genetic elements the 
presence or absence of which determines the clinical outcome 
78 
Extended spectrum of β-lactamase: (ESBL)  
               The ESBL enzymes are plasmid - mediated enzymes capable of hydrolyzing 
and inactivating a wide variety of β-lactams (oxyimino side chain). These 
cephalosporins include cefotaxime, ceftriaxone, and ceftazidime, as well as the 
oxyimino-monobactamaztreonam. 
57
 
        Another common plasmid mediated β-lactamase gene found in Klebsiella 
pneumonia and Escherichia coli are SHV-1 (SulphHydryl in Variable). Over the last 
20 years many new β - lactam antibiotics have been developed which were resistant to 
hydrolytic action of β - lactamases but, because of indiscriminate use, these antibiotics 
alsobecame resistant. To overcome it, around 1980, 3rd generation cephalosporins 
also called broad spectrum Cephalosporins were introduced. Because of their 
extensive use, they also became resistant. Widespread use of third generation 
cephalosporins and aztreonam is believed to be the major cause of the mutations in 
these enzymes that has led to the emergence of the ESBLs
59
.  
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                Various classification schemes have been proposed by many researchers 
since 1968.
60
However, a more modern scheme based on molecular structure 
classification was proposed by Ambler especially of only those enzymes that have 
been characterized.  
               All ESBLs have serine at their active sites except for a small (but rapidly 
growing) group of metallobetalactamases belonging to class B. They share several 
highly conserved amino acid β sequences with penicillin binding proteins (PBPs)61 β--
lactamases attack the amide bond in the betalactam ring of penicillins and 
cephalosporins, with subsequent production of pencillinoic acid and cephalosporic 
acid, respectively, ultimately rendering the compounds antibacterially inactive 
62
 .                    
Plasmids responsible for ESBL production tend to be large (80 Kb or more in size) 
and carry resistance to several agents, an important limitation in the design of 
treatment alternatives 
63
. The most frequent coresistances found in ESBL producing 
organisms are aminoglycosides, fluoroquinolones, tetracyclines, chloramphenicol and 
sulfamethoxazole-trimethoprim 
59.
 
1. Impermeability of the Membrane mediated by both chromosome and plasmid.  
2. Alteration of target protein e.g., Penicillin binding protein.  
3. Increased efflux of the drug from the periplasmic space.  
Characteristics of ESBLs: 
56
 
They are mostly class- A Cephalosporinases carried on plasmids.  
They are more common in Klebsiella species followed by Escherichia coli described 
first in Germany and France.  
1) All enzymes active against Cephalothin.  
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2) Imipenem and Cefoxitin not hydrolysed.  
3) Comparative activity against Cefotaxime and Ceftazidine varies with enzymes.  
4) Some enzymes active against Aztreonam.  
5) Inhibition of activity by β-lactamase inhibitors can be demonstrated.  
Major risk factors for ESBL production: 
               Risk factors are prolonged stay in ICU, long term use of antibiotics, nursing 
home residency, severe illness, high rate of use of Ceftazidime and other Third 
Generation Cephalosporins and use of life lines 
Medical significance of detection of ESBL: 
               Patients having infections caused by ESBL – producing organisms are at 
increased risk of treatment failure with expanded spectrum β-lactam antibiotics. So, it 
is recommended that if an organism is confirmed to produce ESBL it is considered as 
resistant to all 3rd Generation Cephalosporins.  
 Many ESBL isolates will not be phenotypically resistant; even through their 
MIC is so high. ESBL producing strains have been established in many hospitals 
producing epidemic diseases especially in Intensive Care Units.
64
 Failure to control 
outbreaks has resulted in new mutant types in some institution.  
 Staphylococcus aureus was the most frequently isolated pathogenic bacteria 
from post-operative wounds. A majority of the isolates were methicillin resistant 
Staphylococcus aureus (MRSA). Most of the gram-negative bacteria which were 
isolated, ie; Escherichia coli, Proteus mirabilis, Klebsiella species and Pseudomonas 
aeruginosa were sensitive to quinolones and aminoglycosides, but were resistant to 
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cephalosporins. Rest had Enterobacteriaceae, either extended-spectrum β-lactamase 
(ESBL) producers or Amp-C hyperproducers. Indiscriminate use of antibiotics is a 
major problem predisposing patients to harm by multi-resistant pathogens. 
Carbapenems were in use nowadays, but the selection pressure exerted by 
cephalosporins, suggesting a role of single plasmid carrying resistance genes to 
multiple classes.
66
 
Carbapenemases: 
                   Carbapenemases are beta lactamases that cause resistance to carbapenem, 
the β-lactam group with the broadest spectrum of antibacterial action. Carbapenems 
were less susceptible to the inactivating activity of many betalactamases till the recent 
past. But now, even these efficient antibiotics are becoming susceptible to the 
enzymatic inactivation by betalactamases. 
                  The enzymes hydrolysing carbapenems can be grouped into classes A or B 
by molecular analysis. The former has serine as the active site member and the latter 
has zinc at the active site. Since these enzymes are dependent on zinc, a metal, they 
are called Metallobetalactamases. Some class C cephalosporinases can 
hydrolyse/inactivate carbapenems and result in carbapenem resistance, but they are 
not called carbapenemases because they are not carbapenem specific. 
 Antibiotic resistance is rising to dangerously high levels in all parts of the 
world. New resistance mechanisms are emerging and spreading globally, threatening 
our ability to treatand sometimes impossible. Defezz et al., noted that multi drug 
resistance (MDR) in  P. aeruginosa is usually defined as resistance to three or more of 
the antimicrobial agents.
51
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                          4.0. MATERIALS AND METHODS: 
                   This was a Hospital based Prospective Cross sectional study and carried 
out at the Department of Microbiology, Trichy SRM Medical College Hospital and 
Research Centre, Irungalur, Trichy, Tamilnadu. The study was carried out over a 
period of one year (May 2017 to April 2018). 
4.1. Materials: 
                   Consecutive cases of both sexes and all adults belonging to various 
surgical wards and underwent surgical procedure during the study period comprising 
of elective as well as emergency were considered for the present study.  
Patients belonging to anyone of the following were excluded. 
1. Paediatric cases. 
2. Cases taken for second surgery at the same site for any reason. 
3. Patients on immunosuppressant or with immunodeficiency status. 
4. Patients on antibiotics already for any other infections. 
5. Presence of infection elsewhere in the body or focal sepsis. 
                     The work was carried out after getting approval from Institutional 
research board and Institutional ethics committee (copy enclosed – Annexure –I). 
Informed consent (in vernacular) was obtained from every case (model copy of 
informed consent enclosed – Annexure-III). 
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4.2. Patient history 
                       Age, sex demographic details, clinical details including  name of the 
procedure, date and duration of surgery, experience of surgeons, preoperative hospital 
stay, nature of surgery,  antibiotic prescribed (prophylactic/post operative), post 
operative hospital stay, risk factors, onset of illness and other relevant history were 
collected and recorded in a proforma (copy enclosed - Annexure- II). 
4.3 Specimen collection and transport  
            After 48 hours of surgery, dressings on the surgical wounds were removed. 
Evidence of wound infection was considered if the patient had local inflammatory 
changes such as edema, redness, warmth or discharge from wound site. These were 
looked into each case and the changes were documented. If there was any discharge, 
samples were collected before dressing of the wounds. If only inflammatory changes 
were present without any discharge, the wounds were monitored till discharge of the 
patient and for development of discharge from wound. If no inflammatory signs were 
noticed within 48 hrs, cases were followed up with the help of respective surgeons. 
The surgeons incharge of the case was requested to inform/call the postgraduate 
scholar doing this work whenever he/she suspected signs of SSIs in the form of fever 
and local signs of inflammation. In addition, these patients were educated and 
followed up through mobile phone for the development of SSIs over the period of 30 
days. 
4.3.1 Pus swab and aspirate:   
              Preparation of wound site– The suspected as well as overt infected areas were 
cleaned with sterile normal saline followed by 70% alcohol and then the specimen 
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was collected using sterile swab. Two swabs were taken from the depth of the wound 
or lesion and aspirates were collected in a sterile disposable syringe and transported to 
the laboratory within two hours.
79
The color, consistency and odor of the samples were 
observed and recorded.   
4.4. Laboratory works: 
Gram stain:  
                 Direct thin smear was made from each wound swab and/or aspirates on a 
clean grease free glass slide and was air dried. It was then heat fixed and Gram 
staining was done with positive and negative control (ATCC Staphylococcus aureus 
25923 and E.coli 25922). The presence of pus cells and microorganisms was observed 
under the oil immersion (100 X) objective. 
             The samples were cultured onto Nutrient agar, 5% Sheep blood agar and Mac 
Conkey agar plates by adopting standard microbiological techniques. After 24 hrs of 
incubation aerobically at 37°c, plates were read and the isolates were identified based 
on colony morphology, Gram stain, motility and biochemical tests. Antibiotic 
sensitivity test (AST) was performed by Kirby-Bauer disc diffusion method for all 
isolates according to the CLSI 2017 guidelines. Repeat  subculture was carried out on 
next day for samples showing no growth on plates on first day and were processed 
further
80
. All the isolates were identified by colony morphology, microscopic 
appearance, biochemical tests and phenotypic tests for drug resistance. 
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A) Identification of Gram positive cocci: 
              Staphylococcus aureus, Enterococci and Micrococci were identified by 
colony morphology, Gram staining and biochemical test as per standard 
microbiological procedures. 
 i) Staphylococcus aureus, was identified based on the following characteristics 
i.e; gram positive cocci in clusters on Grams staining, golden yellow pigment on 
Nutrient agar plate, positive for catalase and tube coagulase test and showing 
fermentative pattern in Oxidative Fermentative (OF) test of Hugh and Leifson. 
 ii) All coagulase negative gram positive clusters were considered as CoNS. 
 iii) Micrococci were identified based on grams staining and oxidative pattern in 
OF test and excluded as commensal. 
 iv) Enterococci were identified based on microscopic morphology i.e; gram 
positive cocci in diplos, negative for catalase, positive for bile esculin hydrolysis, heat 
tolerence property and mannitol fermentation
80
 . 
Biochemical tests:
81
 
Catalase test: 
It was performed by Tube test with controls. 
A small portion of colony was transferred from the Nutrient agar plate by a clean 
platinum wire or glass rod into a tube containing 3% hydrogen peroxide.  
Positive control: Staphylococcus aureus 
Negative control: Streptococcus sp 
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Interpretation: 
Positive - Evolution of effervescence within 10 seconds 
Negative – no or delayed   effervescence 
Coagulase test:  
This was performed by slide test (for detecting bound coagulase) and tube test (for 
detecting free coagulase).  
Slide Coagulase Test:  
The suspected Staphylococcal colony was emulsified in a drop of water on a 
microscope slide. A flamed and cooled straight inoculating wire was dipped into the 
undiluted plasma at room temperature, the adhering traces of plasma was stirred into 
the Staphylococcal suspension on the slide with control.  
Positive – Coarse visible clumping within 10 seconds 
Negative - Absence of clumping in less than 10 seconds.  
Tube coagulase test:  
A 1/6 dilution of the plasma was prepared in normal saline (0.85%Nacl) and 1ml 
volume of the diluted plasma was taken in a small tubes. A colony of Staphylococcus 
was emulsified in a test tube with diluted plasma. It was incubated at 37ºC for up to 4 
hours. The tubes were examined at 1, 2 and 4 hours for clot formation by tilting the 
tube through 90º. The negative tubes were left at room temperature overnight and re-
examined. 
Positive control: Staphylococcus aureus ATCC 25923 
Negative control: Staphylococcus epidermidis 
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Interpretation: 
Positive - Any degree of clot formation 
 Negative - If the plasma remained liquid or showed only a flocculent or ropy 
precipitate. 
 Bile Esculin hydrolysis:  
One to two colonies from an 18 to 24 hours growth on nutrient agar plate was 
inoculated on to the surface of the bile esculin agar slant. It was incubated at 35ºC in 
ambient air for 48 hours.  
Positive control: Enterococcus spp 
Negative control: Viridans streptococcus 
Interpretation: 
Positive - Blackening of the agar slant  
Negative - no colour change. 
B) IDENTIFICATION OF GRAM NEGATIVE BACILLI (GNB)  
  The gram negative bacilli were identified based on the colony morphology, motility, 
catalase test, oxidase test, indole test, Methyl red, Voges Proskauer, triple sugar iron 
agar, citrate utilisation and urease production. 
Oxidase test:  
It was performed by picking a colony using platinum loop or glass rod. The colony 
was tested on freshly prepared solution of 1% oxidase reagent (tetra methyl 
paraphenylene diaminedihydro chloride) with control. 
Positive control: Pseudomonas aeruginosa ATCC 27853 
Negative control: Escherichia coli ATCC 25922 
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Interpretation: 
Positive –  deep purple colour change within 10 seconds. 
Negative – colour change after 10 seconds. 
Indole test: 
The organism was inoculated into peptone water and incubated for 24 hrs. Later, 
Kovacs reagent was added. If the color changed to red on the top of the test tube it 
was considered as positive.  
Positive control: Escherichia coli ATCC 25922 
Negative control: Klebsiella pneumoniae 
Interpretation: 
 Positive – Red coloured ring  
 Negative – Yellow coloured ring  
Methyl red test (MR):  
The gram negative bacteria from a 24 hrs growth culture was inoculated in glucose 
phosphate broth and  incubated at 35ºC to 37ºC for 48 to 72 hrs aerobically. Then 5 to 
6 drops of 0.04% solution of Methyl red was added. The results were read 
immediately after mixing well. 
Positive control: Escherichia coli ATCC 25922 
Negative control: Enterobacter aerogenes 
Interpretation: 
Positive – stable bright red color in the surface of medium. 
36 
 
Negative – no colour or intermediate orange colour change. 
Voges Proskauer test (VP):  
The test organism was inoculated in glucose phosphate broth and incubated at 35°C to 
37ºC for 48 to 72 hours. 6 drops of solution A (alpha naphthol) and 2 drops of solution 
B (KOH) were added to 1 ml of the broth and was observed after mixing well for 5 
minutes.  
Positive control: Enterobacter aerogenes 
Negative control: Escherichia coli ATCC 25922 
Interpretation: 
Positive - Red color within 15 minutes or more after addition of reagent. 
Negative – no colour change or copper colour after 1 hour.  
Citrate utilization test:  
Bacterial colony was picked by touching the tip of the needle on the colony that was 
18 to 24 hrs old and inoculated into solid (Simmon‘s) media with indicator 
bromothymol blue, lightly on the slant and incubated at 37ºC. Then it was observed 
for development of blue color and growth.  
Positive control: Enterobacter aerogenes 
Negative control: Escherichia coli ATCC 25922 
Interpretation: 
Positive - Intense blue color and/ or growth on the slant.  
Negative - No change in color and growth  
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Christensen‟s urease test:  
The test was done by using Christensen‘s medium. The organism was inoculated on 
the entire slope of the medium and overnight incubated at 37°C for up to 7 days.  
Positive control: Proteus spp 
Negative control: Escherichia coli  ATCC  25922 
Interpretation: 
Positive – Pink Colour  
Negative – Pale yellow colour  
Triple sugar iron (TSI) test:  
The medium was inoculated with bacterial culture using a straight wire (Stab culture) 
and then streaked on the slant. It was incubated at 37°C 24 to 48 hours.  
Interpretation: 
Acid / Acid with gas – Glucose and Lactose/ Sucrose fermenter  
Alkaline / Acid– Glucose fermentor 
 Alkaline / Acid with abundant black colour – Glucose fermentor with Hydrogen 
sulphide production 
Alkaline / Alkaline – Non fermenting GNB  
Nitrate reduction test:  
The test organism was inoculated with one drop from a 24 hrs nitrate broth culture 
which was incubated at 35ºC for 48 – 72 hrs. It was then examined for nitrogen gas in 
the inverted Durham tubes and 5 drops of nitrate reagent A and B (sulphanilic acid 
and α–naphthylamine) were added. It was observed for 3 min for red color to develop.  
Positive control: Escherichia coli ATCC 25922 
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Negative control: Acinetobacter baumannii 
Interpretation: 
Positive - Red color change within 30 seconds 
Negative – no colour change 
Table no.7: Biochemical reactions and isolation of microbes
81
: 
 
 
GNB-Gram negative bacilli, I – Indole, MR – Methyl Red, VP- VogesProskauer, 
C- Citrate, U- Urease, MMM- mannitol motility medium, NR – Nitrate 
Reduction, TSI –Triple Sugar Iron, A- Acid, K- alkaline, + Hydrogen sulphide 
production, ND- not done.  
 
Organisms  Grams  Catalase  Oxidase  I NR MR VP C TSI U MMM 
E.coli GNB  + - + + + - - A/A - +/+ 
K.pneumoniae GNB + - - + - + + A/A + +/- 
K.oxytoca GNB + - + + - + + A/A + +/- 
Proteus spp GNB + - - + + - + K/A
+ 
+ -/+ 
Enterobacterspp GNB + - + + - + + A/A - +/+ 
Citrobacterkoseri GNB + - + + + - + A/A - +/+ 
Pseudomonas 
aeruginosa 
GNB + + - + ND ND + K/K - -/+ 
Acinetobactersp GNB + - - - ND ND +/- K/K - -/- 
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4.5. ANTIMICROBIAL SENSITIVITY TESTING
80
 
              The antimicrobial sensitivity testing for all the isolates was done on Muller 
Hinton Agar by Kirby – Bauer disc diffusion method as per CLSI 2017 guidelines 
using antibiotic discs (Himedia, Mumbai) 
I. Kirby Bauer Disk Diffusion Test: 
Preparation of turbidity standard: 
              McFarland 0.5 standard was prepared by adding 99.55 ml of 1% Suphuric 
acid and 0.5 ml of 1.175 % barium chloride. This solution was dispersed into tubes 
comparable to those used for inoculum preparation. It was sealed tightly and stored in 
the dark at room temperature. The McFarland 0.5 standard provides turbidity 
comparable to that of a bacterial suspension containing approximately 1.5 X 10
8
 
CFU/ml.  
Preparation of Inoculum:  
             In order to prepare the inoculum, about 3-5 representative colonies were 
picked up and inoculated in 4 - 5 ml of peptone water and incubated at 37ºC for 2 – 6 
hrs to attain 0.5 McFarland‘s standard and if it was found more turbid, then some 
more quantity of peptone water was added and adjusted to 0.5 McFarland‘s standard 
by comparing against a card with white background and contrasting black lines.  
Inoculation of Muller Hinton Agarplates: 
           Within 15 minutes of adjusting the turbidity of the inoculum suspension, a 
sterile cotton swab was dipped into broth and rotated several times. During this 
process, the swab was pressed firmly on the inside wall of the tube above the fluid 
level to remove excess of broth from the swab. Then, the dried surface of Muller 
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Hinton agar plate was inoculated by streaking the swab over the entire sterile agar 
surface. This procedure was repeated by streaking two more times by rotating the 
plates at an angle of approximately 60ºc to ensure an even distribution of inoculum 
and finally, the rim of the agar was swabbed. The plate was closed and left for 3-5 
minutes to allow any excess surface moisture to be absorbed before applying 
antibiotic impregnated discs.  
Application of discs to inoculated agar plates: Disc container was taken out from 
refrigerator one or two hours before use and brought to room temperature. Once a 
cartridge of discs has been removed from its sealed package, it was replaced in a 
tightly sealed dry container after use in refrigerator. The entire discs were placed on 
agar plates and pressed down to ensure complete contact with the agar surface. Discs 
were distributed evenly so that they were not closer than 25 mm from centre to centre 
of the disc and incubated at 37º C for 16 – 18 hrs. 
Reading and interpretation of results:  
After 16-18 hrs of incubation, each plate was examined for satisfactory streaking with 
confluent lawn of growth uniformly and circular zones of inhibition. The diameter of 
the zones of complete inhibition including the diameter of the discs was measured. 
The zones were measured to the nearest millimeter using a ruler that was held on the 
back by inverting Petri plate. The Petri plate was held a few inches above a black, non 
reflecting background and illuminated with reflected light. The zone margin showing 
no obvious visible growth that could be detected with unaided eyes was considered as 
a zone of inhibition. The sizes of the zones of inhibition were interpreted as per CLSI 
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standards and reported as ‗susceptible‟, „intermediate‟ or „resistant‟ to the drugs 
that were tested.  
A bacterium can be 
Susceptible – when it is inhibited by the concentration of the drug usually used 
Intermediate – when it is susceptible to drug at higher than normal dosages 
Resistant – when it is not inhibited by the drug82 
Control strains used with each batch:  
i. Escherichia coli ATCC 25922  
ii. Pseudomonas aeruginosa ATCC 27853  
iii. Staphylococcus aureus ATCC 25923 
iv.  Enterococcus faecalis ATCC  29212 
Table no.8: List of antibiotics tested: 
As per CLSI 2017 guideliness
83 
Gram positive cocci Gram negative bacilli 
Penicillin(10U)  
Ampicillin (10 μg),  
Erythromycin (15 μg),  
Clindamycin (2 μg),  
Gentamicin (10 μg), 
 Co-trimoxazole (1.25/ 23.75 μg), 
 Tetracycline (30 μg),  
Ciprofloxacin (5 μg)  
High level gentamycin(120 μg) 
Linezolid (30μg)) 
Ampicillin (10 μg) 
Amoxclav(20/10μg) 
Amikacin (30 μg) 
Gentamycin(10μg)  
Ciprofloxacin (5 μg) 
Trimethoprim/sulfoethoxazole 
(1.25/23.75μg)  
Ceftriaxzone (30 μg) , 
Cefotaxime (30 μg) 
Ceftazidime (30μg)  
Cefepime (30μg ) 
Piperacillin/ tazobactum (180/ 18 μg) 
Imipenem(10 μg) 
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4.6. Detection of MRSA:  
                 MRSA isolates were detected by standard disc diffusion method using 
Cefoxitin (30µg). Cefoxitin is considered as a better inducer of mec-A gene than 
oxacillin or methicillin, and can be used to screen heterogeneous MRSA populations. 
As per CLSI 2017 guidelines, zone of inhibition ≤ 21 mm was considered as 
Methicilin resistant isolates.
84 
 
Fig 3 - Cefoxitin disc diffusion method for detection of MRSA ZOI  ≤ 21 mm. 
 
4.7. Detection of Extended Spectrum Betalactamases: 
 As per CLSI 2017 guidelines, the test isolates which  showed  an inhibition 
zone of  ≤27mm for cefotaxime (CTX),  ≤25mm for Ceftriaxone(CTR)   and ≤ 22mm  
for  Ceftazidime (CAZ)  were considered as  presumptive  ESBL producer.  All these 
isolates were further tested for phenotypic confirmation test for ESBL. 
Phenotypic Confirmation Test:  
                 Antibiotic susceptibility testing was done on Muller Hinton Agar with 0.5 
McFarland‘s standard of the organism85.  
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               Lawn culture of the organism was made and 3rd generation cephalosporin, 
Ceftazidime and Cefotaxime (30μg) disc was tested alone and along with their 
combination for 10µg of Clavulanic acid. Organisms with 5mm increase in zone of 
inhibition for Ceftazidime and Cefotaxim / Clavulanic acid (30μg/10μg) are 
confirmed as ESBLs. 
86,87
.  
 Indicators of ESBLs: 5 mm increase in diameter of inhibition zone when using disc 
diffusion method with 3rd generation Cephalosporin and Clavulanic acid combined 
disc. 
 
Figure no.4: Combined disc test of ESBL producers 
4.8. DETECTION OF AMP C PRODUCERS 
 As per CLSI 2017 guidelines, the test isolates which showed an inhibition zone 
of ≤ 18 mm for Cefoxitin disc (30µg) were considered as presumptive Amp C 
producer. All these isolates were further tested by Amp C disk test. 
AMP C DISK TEST:  
 All the Cefoxitin resistant strains were subjected to Amp C disk test to detect 
the production of Ambler class C β-lactamase.88 
Cefotaxime + clavulanic acid 
Cefotaxime 
Ceftazidime 
Ceftazidime + clavulanic acid 
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 An overnight culture suspension of ATCC E.coli25922 was prepared in 
peptone water, matched to 0.5 McFarland turbidity standards and inoculated as 
lawn culture over a 90mm MHA plate as for routine disk diffusion procedure.
89
 
 A Cefoxitin disk with a potency of 30 microgram was placed over the lawn.  
 An empty disk moistened with sterile saline and inoculated with the test 
organism was placed at the vicinity of the Cefoxitin disk almost touching it. 
The culture plate was kept in the incubator for overnight incubation at 37° C.
88
 
 Blunting of the zone of inhibition of cefoxitin near the test strain inoculated 
disc was taken as indicative of the strain being a producer of Ambler class C 
betalactamase, as shown in Fig no.5. 
 The results were recorded and tabulated. 
 
                         
                         Figure no.5:   Amp C disc test 
4.9. Detection of Carbapenemase producing organisms: 
 As per CLSI 2017 guidelines, the test isolates which showed an inhibition zone 
of imepenem were subjected to combined disc test. 
 
 
45 
 
Table no.9: Disc diffusion - CLSI guidelines for Carbapenems:  
Antibiotic  S (mm)  I (mm)  R (mm)  
Enterobacteriaceae 
Meropenem ≥23  20-22  ≤19  
Imipenem ≥23  20-22  ≤19  
Pseudomonas aeruginosa 
Meropenem ≥19 16-18 ≤15 
Imipenem ≥19 16-18 ≤15 
Acinetobacter spp 
Meropenem ≥18 15-17 ≤14 
Imipenem ≥22 19-21 ≤18 
 
4.10. MODIFIED HODGE TEST:  
 An overnight culture suspension of ATCC E.coli25922 was prepared in 
peptone water, matched to 0.5 McFarland turbidity standards, diluted to one in 
ten and inoculated as lawn culture over a 90mm MHA plate as for disk 
diffusion
.90
 
 After waiting for 3-5 mins for drying, a Meropenem disc was placed at the 
centre of the plate.  
 Using a loop which can deliver 10 microlitre, the test organism was taken and 
streak inoculated from the disk edge towards all four directions. 4 isolates were 
tested in a plate with a single Meropenem disc. The plate was incubated at 
37°C for 16-20 hrs.  
 The plates were examined the next day for enhanced growth around the test 
organism and the zone of inhibition giving a clover leaf appearance, which was 
indicative of Carbapenemase production
90
 as shown in Figure no.6. The results 
were recorded and tabulated.  
46 
 
Figure no.6. Modified Hodge test    
 
4.11. Ten disc method:
91
 
         This procedure helps in screening of a bacterial isolate for all β-lactamases 
(ESBLs, AmpC and Carbapenemases). Aztreonam (30μg), Cefotaxime (30μg), 
ceftazidime (30μg), Cefotaxime + clavulanic acid(30/10), ceftazidime + clavulanic 
acid(30/10μg), Ceftriaxone (30μg), Cefoxitin (30μg), Cefepime, Imipenem(10μg), 
Imipenem + EDTA are the drugs for which the sensitivity of the organisms is detected 
, by using Kirby Bauer disc diffusion assay. 
Detection of ESBLs: 
Ceftazidime or cefotaxime discs with and without clavulanic acid are used to detect 
ESBLs. If the zone increases by 5mm or above with clavulanic acid combination, the 
isolate is an ESBL producer. 
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Detection of AmpC β-lactamases:  
Amp C β-lactamases are resistant to Cefoxitin and Cefotetan. High level AmpC 
producers are even resistant to Carbapenems and Aztreonam.
91
 
Detection of Metallobetalactamases: 
Imipenem or Meropenem discs with and without EDTA are used to screen for 
carbapenemases. If the zone increases by 7mm or above with EDTA combination, the 
isolate is an MBL producer. 
 
 
Figure no.7. Ten disc procedure 
The data were entered in the Microsoft Excel sheet and analyzed using SPSS. 
 
 
Meropenem + EDTA 
Meropenem 
Cefotaxime + clavulanic acid 
Cefotaxime 
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                                              5.0. RESULTS  
                The study, “Bacteriological Profile, Antibiogram and Risk Factors of 
Surgical Site Infections in a Tertiary Care Hospital” was carried out in the 
Department of Microbiology, Trichy SRM Medical college Hospital and research 
centre, Trichy and the results were analyzed for the Surgical site infections (SSIs) rate 
as per class of wound, type of surgery, antibiotic prophylaxis, risk factors, drug 
resistance and American society of anesthesiologist index..  
5.1. Prevalence of SSIs:  
    A total of 2076 patientsunderwent different types of surgeries comprising of 
elective as well as emergency during a 12-month period (May 2017 – April 2018). 
The types of surgeries done in this hospital during the study period are listed in the 
table no.10. During the 12 consecutive months of study period, 116 surgical site 
infections were documented and hence,the overall prevalence of surgical site infection 
rate during the study period was 5.6%(n=116). Among the 2076 surgeries, abdominal 
surgeries constituted (n =739; 35.6%) the highest rate of SSI occurred in the category 
of exploratory laparotomy. 78 underwent exploratory laparotomy, 20 developed SSIs 
(25.6%). The number of cases who developed SSIs in relation to type of surgery are 
shown in table no.10. 
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Table no.10: Types and number of surgeries carried out (May 2017- April 2018) 
Site of surgery  Types of surgeries No. of 
surgeries 
 N=2076 
SSI(5.6%) 
N=116 
Abdomen (N=739) Appendectomy  82(3.94%) 13(15.6%) 
Hernia repair 86(4.14%) 16(18.6%) 
Exploratory laparotomy 78(3.7%) 20(18.6%) 
Cholecystectomy  67(3.22%) 12(17.9%) 
LSCS 266(12.8%) 6(2.2%) 
Hysterectomy  160(7.7%) 4(2.5%) 
Pelvis (N=154) Sphincterotomy 43(2.0%) 2(4.6%) 
Hemorrhoidectomy 41(1.97%) 4(9.7%) 
Fistulectomy 39(1.87%) 2(5.1%) 
Hip replacement 31(1.58%) 6(19.3%) 
Urogenital (N=91) Transuretheral Resection of Prostate 25(1.2%) 2(8%) 
Uretheroscopic lithotripsy 66(3.17%) Nil  
Breast & axilla 
(N=85) 
Modified Radical Mastectomy 24(1.1%) 3(12.5%) 
Fibroadenoma excision 61(3.02%) Nil  
Skin, Bone & 
Joints(N=302) 
Knee replacement 47(2.26%) 4(8.5%) 
Varicose vein 41(1.97%) Nil  
Open Reduction and Internal 
Fixation 
214(10.3%) 13(6.0%) 
Eye  Intraocular lens implantation 454(21.8%) Nil  
ENT (N=219) Tonsillectomy  123(5.92%) 2(1.6%) 
Mastoidectomy 96(4.62%) Nil 
 Neurosurgery  32(1.54%) Nil  
                             Total                                                             2076 116 
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Table no.11: Comparison between site of surgery and organism isolated 
Site  S.aureus 
(32) 
Entero
cocci 
spp(3) 
E. coli 
(27) 
Kleb 
spp 
(19) 
Proteus  
Spp (7) 
Citrobacter 
spp (1) 
Entero 
bacter 
spp (7) 
P.aeruginosa 
(19) 
A. baumanii 
(9) 
Abd 43% 100% 70% 52.6% 57.1% 100% 100% 52.6% 44.4% 
Ortho 15% - 30% 26.3% 28.5% - - 15.7% 22.2% 
Pelvis 19% - - 21% - - - 10.5% 22.2% 
Breast 9% - - - - - - - - 
ENT 12% - - - 14.2% - - 10.5% 11.1% 
Uro - - - - - - - 10.5% - 
 
Abd- Abdomen, Uro- Urology, ENT- Ear, Nose and Throat. 
All the above organisms were isolated in abdominal surgeries ranging from 43% to 
100%. In pelvic surgeries, Acinetobacter baumanii and Klebsiella spp were commonly 
encountered whereas it was E.coli and Proteus mirabilis in orthopedic surgeries. 
5.2. GENDERWISE DISTRIBUTION OF SSI:  
            Among the 1297males who underwent surgery, SSIs were seen in 84 (6.4%) of 
them and among the females (779) it was noticed in 32 (4.1%). The odd‘s ratio was 
1.61. Distribution of cases in relation to gender is given in table no.12. 
Table no.12: Distribution of cases in relation to gender 
No Infected  Not infected Total  
Males  84 1213 1297 
Females  32 747 779 
Total  116 1960 2076 
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5.3. AGE WISE DISTRIBUTION OF SSI:  
          The age of the study subjects ranged from 16 years to 72 years. 33 (28.4%) of 
them belonged to >55years of age followed by 29 (25%) and 25 (21.5%) in 35-44 
years and 45-54 years respectively. The least belonged to below 35 years. The 
distribution of the SSI in relation to age group is depicted in figure no.8 and in relation 
to age group is given in table no.13. The odd‘s ratio for the development of SSIs 
among those below the age of 25 was 2.45. 
Figure no.8: Age wise distribution of SSIs 
 
Table no.13: Distribution of SSIs and age group 
Age group  No of cases  SSIs % 
16 – 24 109 13 11.9 
25 - 34 237 16 6.7 
35 – 44 556 29 5.2 
45 -54 501 25 4.9 
> 55  673 33 4.9 
Total  2076 116  
 
13
16
29
25
33
16-24 yrs 25-34 yrs 35-44 yrs 45-54 yrs >56 yrs
N = 116
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5.4. COMPARISION OF SSI IN ELECTIVE VS EMERGENCY SURGERIES: 
 The present study which included 1820 elective surgeries and 256 emergency 
surgeries, in which SSI rate was 5.16%   and 8.59%   respectively. Emergency 
surgeries showed higher rate of SSI as compared to elective surgeries and shown in 
figure no.9. The odd‘s ratio was 0.57. The distribution of the cases and occurrence of 
SSIs are furnished in table no.14. 
 
 
Table no.14: Distribution of SSIs and category of surgery 
Category  Infected  Not infected Total   
Elective 94 1726 1820 
Emergency 22 234 256 
Total  116 1960 2076 
 
 
 
Elective Emergency
1820
256
94
22
No of Surgery SSI
Figure no.9: Comparison of Elective vs Emergency surgeries 
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5.5. DISTRIBUTION OF SSI BASED ON NATURE OF WOUND: 
 Among 2076 patients, 1307 underwent clean surgeries, of these 42 developed 
SSI (3.2%). The occurrence of SSIs among clean contaminated (n=519), contaminated 
(n=187) and dirty wounds (n=63) were 5.2%,11.2% and 41.2% respectively. The 
distribution of SSIs in relation to nature of wound is provided in figure no.10. 
Figure no.10. Distribution of SSIs and nature of wound
 
 
5.6. TYPE OF SSI BASED ON EXTENT OF WOUND: 
 As per CDC, SSI has been categorized into superficial, deep and organ/ space 
SSIs. In the present study, it was observed that 69 (59%) had superficial SSI and the 
rest (n=47) deep ones. There were no organ /space SSIs observedduring the study 
period and their distribution is depicted in figure no.11. 
Clean Clean 
contaminated
Contaminated Dirty
Total surgeries 1307 519 187 63
No of SSI 42 27 21 26
Rate of SSI 3.20% 5.20% 11.20% 41.20%
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Figure no.11: Distribution of SSIs and extent of wound 
 
5.7. RISK FACTORS OF SSIs: 
 All 116 SSI occurred in patients who had one or more risk factors like diabetes 
mellitus, smoking, alcohol, blood transfusion etc. Among them 7 (6.03%) had only 
single risk factor (diabetes mellitus), 23(19.8%), 40 (34.4%), 34(29.3%) and 
12(10.3%) had combination of 2, 3, 4 and 5 risk factors respectively. 
Table no.15: Distribution of risk factors among SSIs 
Risk Factors SSI  N = 116 Percentage  
Diabetes mellitus 64 55.1% 
Smoking  49 42.2% 
Alcoholism 41 35.3% 
Anaemia 31 26.7% 
Hospital stay 
1-7 days 
>7 days 
 
27 
89 
 
23.2% 
76.7% 
Drain 18 15.5% 
 
59%
41%
0%
Superficial Deep
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The distribution of cases with SSIs in relation to ASA score are provided in table 
no.16. 
Table no.16: Distribution of ASA score along with SSIs 
ASA SSIs % 
I 16 13.7% 
II 35 30.1 
III 59 50.8 
IV 6 5.17 
V Nil  Nil  
 
 Though all the cases received prophylactic antibiotics before and after surgery, 
116 developed SSIs. The category of antibiotics used either alone or in combination 
and the development of SSIs are shown in table no.17. 
Table no.17: Distribution of SSIs in relation to prophylactic antibiotic usage 
  Antibiotics  No  % 
Single drug < 5 days 39 32.4% 
Single drug > 5 days 22 11.2% 
Multiple drug < 5 days 42 36.8% 
Multiple drug > 5 days 13 19.2% 
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5.8. Laboratory works: 
 The occurrence of inflammatory signs were noticed on 4
th
 day of surgery in 12 
cases, 5
th
 day in 76 cases and 6
th
 day in 46 cases. Hence, the samples were collected 
from the respective cases and subjected to microbiological studies. Culture was 
positive among 116 of 134 samples. Among the 134 samples, 93 (69.4%) belonged to 
wound swabs and the rest (n=41; 30.6%) were wound aspirates. The details of the day 
of sample collection and its association with culture positivity are depicted in table 
no.18. 
Table no.18: Day of sampling and surgical infections. 
SL.NO Day of sampling Inflammatory 
signs 
Culture report % 
1. 48 hrs (Day 2) - - - 
2. 96 hrs (Day 3) - - - 
3. Day 4 12 05 41.2% 
4. Day 5 76 69 90.7% 
5. Day 6 46 42 91.3% 
Gram staining: 
 These cases were classified into those who showed< 20 pus cells per oil 
immersion field or more than that. An attempt was made to find out the association 
between presence of pus cells and culture positive status. Microscopic studies of the 
gram stained smear showed pus cells in 122/134 (91%) and microorganisms in 37/134 
(27.6%). The distribution of pus cell in relation to culture positive status is given in 
table no.19. 
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Table no.19: Distribution of pus cells and culture positivity 
Culture status                    Pus cells/oil immersion field Total  
< 20 >20 
Positive 32 84 116 
Negative  13 05 18 
Total  45 89 134 
 
 After distributing the data in2/2 table an attempt was made to find out positive 
predictable value. Positive predictable value for culture (0.27) was high among those 
who had > 20 pus cells/ oil immersion field, thereby indicating that greater the number 
of pus cells more the chance of getting positive culture and irrespective of the 
presence of bacteria. 
Table no.20: Association betweengram stain and culture positivity 
Microorganisms in 
smear 
                         Culture    Total  
+ - 
Present  32 5 37 
Absent  84 13 97 
 116 18 134 
 
 Since the smear studies were made at the bedside to look for pus cell and 
bacteria, an attempt made to distribute the results as shown in below table no.21. The 
odd‘s  ratio was 0.99. 
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 Table no.21: Association between pus cells and microorganisms in smear 
Microorganisms in 
smear 
Pus cells/ oil immersion field   Total  
<20 >20 
Present  17 20 37 
Absent  28 69 97 
 45 89 134 
 
              Subsequent analysis of the number of pus cells with smear studies revealed 
that the presence of pus cells were more important than seeing bacteria alone in gram 
staining. The odd‘s ratio was 2.09. 
             Higher culture positivity (72.4%) was seen in those patients whose smear had 
more no of pus cells and it was significant statistically (p=<0.01) in contrast to those 
who showed presence of bacteria but no pus cells. These observations indicate much 
weightage for the presence of pus cells. In otherwords, simple examination of 
discharge for pus cells may be a clue for SSIs for the practitioner. 
5.9. DISTRIBUTION OF VARIOUS BACTERIA IN SSI: 
 In our study, bacteria were isolated from 116/134 samples subjected to culture. 
108 samples showed monomicrobial growth and 8 showed polymicrobial growth 
(E.coli + Staphylococcus aureus =2, P.aeruginosa + E.coli =3, Acinetobacter 
baumanii + Staphylococcus aureus = 2, E.coli + Acinetobacter baumanii = 2). So, 
atotal of 124 isolates were obtained. Among them, 35(28.2%) were gram positive 
cocci. of the 89 gram negative bacilli, there were 61(68.5%) Enterobacteriaceae and 
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28 (31.4%)  non fermentors. The details have been furnished in Figure no.12.below.
 
 Among the 35 gram positive cocci 32(91.4%) were Staphylococcus aureus and 
3 (8.5%) were Enterococci spp. Out of 61 Enterobacteriaceae 27(44.4%) were E.coli, 
19(31.1%) Klebsiella spp., which included 17 Klebsiella pneumonia and 2 Klebsiella 
oxytoca, 7(11.4%) Proteus mirabilis, 7 (11.4%) Enterobacter spp and 1(1.63%) 
Citrobacter freundii. The remaining 28 were Non fermenters: 19 (67.8%) 
Pseudomonas aeruginosa and 9 (32.1%) Acinetobacter baumanii. The isolates are 
depicted in figure no.13 
 
 
28%
72%
Figure no.12. Distribution of gram positive and gram 
negative organisms in SSIs
Gram positive cocci Gram negative bacilli
32
3
27
19
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FIGURE NO.13:DISTRIBUTION OF ORGANISMS IN SSI(N=116)
Staphylococcus aureus Enterococci E.coli
Klebsiella spp Proteus mirabilis Enterobacter spp
Citrobacter freundii Pseudomonas aeruginosa Acinetobacter baumanii
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5.10. Antimicrobial susceptibility pattern: 
There were 32 Staphylococcus aureus and 3 Enterococcus spp isolated during the 
study period and the sensitivity pattern is given in the table no.22. 
Table no.22. Antimicrobial susceptibility pattern in gram positive cocci 
Antibiotics Staphylococcus aureus 
N=32  
Enterococcus spp 
N=3 
Penicillin (10U) 1.2% 0 
Doxycycline (30μg) 43.7% 66.6% 
Erythromycin (15μg) 46..8% 100% 
Clindamycin (2μg) 40.6% - 
Gentamycin (10μg) 68.7% - 
Amikacin(30μg) 81..2% - 
Ciprofloxacin (5μg) 65.6% 33.3% 
Cotrimoxazole(1.25/23.75μg) 37.5% - 
Tetracycline (30μg) 40.6% 33.3% 
Linezolid (30μg) 100% 100% 
High level 
gentamycin(120μg) 
- 100% 
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 Among 32 Staphylococcus aureus isolates from SSI, 11 were MRSA strains 
(37.9%) and the remaining 21 (62%) were MSSA as shown in fig no.14 
 
MRSA – Methicillin resistant Staphylococcus aureus, MSSA- Methicillin sensitive 
Staphylococcus aureus 
The antibiotic susceptibility of gram negative bacilli are furnished in table no.23 given 
below 
Table no.23: Antibiotic susceptibility pattern in gram negative bacilli: 
Antibiotics  E.coli(27) Kleb 
spp(19) 
Proteus 
spp(7) 
Enterobacter 
spp(7)  
P.aeruginosa 
(19) 
Acinetobacter 
spp (9) 
AMP   3.7% 0 0 14.2% 0 0 
AMC   14.8% 0 0 14.2% 0 0 
CIP   44.4% 31.5% 71.4% 71.4% 36.8% 22.2% 
COT   55.5% 31.5% 71.4% 57.1% 31.5% 22.2% 
GEN   66.6% 52.6% 57.1% 85.7% 47.3% 11.1 
AK  77.7% 63.1% 71.4% 85.7% 52.6% 22.2% 
CTR  40.7% 36.8% 85.7% 57.1% ND 11.1% 
CTX 40.7% 36.8% 85.7% 71.4% ND 11.1% 
CAZ 44.4% 42.1% 71.4% 57.1% 63.1% 22.2% 
CPM 62.9% 57.8% 85.7% 85.7% 63.1% 22.2% 
AT  85.1% 73.6% 71.4%  71.4% 68.4% 22.2% 
CX 77.7% 73.6% 85.7% 71.4% 68.4% 33.3% 
IPM 88.8% 84.2% 85.7% 85.7% 78.9% 33.3% 
PIT 96.2% 89.4% 100% 85.7% 84.2% 55.5% 
 
MSSA
62%
MRSA
37.9%
Figure no.14:Frequency of MRSA in 
SSIs
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The gram negative organisms were further tested for production of various enzymes 
like ESBL, Amp C and MBL. The details are described in the ensuring paragraph. 
5.11. DISTRIBUTION OF ESBL PRODUCING GRAM NEGATIVE BAILLI IN 
SSIs: 
Out of 61 Enterobacteriaceae, 28 were ESBL producers (46%) on combined disc test. 
Among them 15 (53.5%) were E.coli, 11(39.2%) were Klebsiella spp, 2 (7.0%) were 
Enterobacter spp as shown in figure no.15 
Figure no.15: Distribution of ESBL producers in SSIs 
 
5.12. DISTRIBUTION OF AMP C PRODUCERS IN SSIs: 
In the present study, out of 89 gram negative bacilli, 15(16.8%) were Amp C 
producers, out of which 6 were Pseudomonas aeruginosa, 4 Acinetobacter baumanii, 
1E.coli, 3 Klebsiella spp and 1 Enterobacter spp which are depicted in figure no.16. 
 
 
 
E.coli
54%
Klebsiella
39%
Enterobacter
7%
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Figure no.16: Distribution of Amp C in SSIs 
 
5.13. DISTRIBUTION OF MBL IN SSIs: 
 Out of 89 gram negative bacilli, 12 (13.2%) were Metallobetalactamase 
producers on Modified Hodge test as shown in the figure no.17. (5 out of 9 
Acinetobacter spp (41.6%), 4 out of 17 Pseudomonas aeruginosa (33.3%), 1 out of 27 
E.coli (8.3%) and 2 out of 19 Klebsiella spp (16.6%). 
                           Figure no.17: Distribution of MBL producers in SSIs 
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5.14. DISTRIBUTION OF MULTIDRUG RESISTANCE IN SSIs: 
 Out of 124 isolates, 44 were resistant to more than 3 groups of antimicrobial 
drugs (35.4%) which included Staphylococcus aureus 11, Pseudomonas aeruginosa 9, 
Acinetobacter spp 6, Klebsiella spp 9,  E.coli 7, Proteus mirabilis 2 and are shown in 
figure no.18. 
                     Figure no.18:  Distribution of MDR in SSIs 
 
 No MRSA carrier was identified in the present study. During the study period, 
none of them had hypothermia, hypoxia or shock status. Chlorhexidine bath 
preoperatively was not adopted for the cases. Razor was used for removal of hair for 
all patients undergoing surgery. 
 No significant difference was observed with regard to duration of surgery, 
experience of surgeon or excess trauma to the tissues as the surgeries were carried out 
Staphylococcus 
aureus
18% (11)
E.coli
22%(7)
Klebsiella spp
14%(9)
Proteus spp
7%(1)
Pseudomonas
18%(9)
Acinetobacter spp
21%(6)
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by senior surgeons. Standard aseptic procedureswere adopted by all surgeons and 
sterility of the operation theatre was monitored and maintained. 
 The patients were followed up from 24 hours after surgery till discharge with 
the help of respective surgeons for signs of local and systemic infection. Only 4 cases 
developed complications and underwent secondary surgery. 
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                                           6.0. DISCUSSION 
 Surgical site infections (SSIs) are a worldwide problem that has far reaching 
implications on patient morbidity and mortality, and also has impact in thecost of 
treatment. It is the third most common nosocomial infection, and the frequency of 
SSIs  varies from hospital to hospital. Watanabe et al reported SSIs in 15%
92
of their 
series whereas Leigh Neumayer et al reported 38%
93
. 
 In our study, 2076 patients underwent various surgeries. Among them 739 
patients underwent various abdominal surgeries like exploratory laparotomy, hernia 
repair, appendectomy, hysterectomy, etc. 302 patients had undergone orthopedic 
procedures like ORIF, hip & knee replacement etc. and 154 and 85 underwent pelvic 
and breast surgeries respectively.When compared with other studies, Allegranzi B et 
al, Azoury SC et al and Emil Aga et al also reported abdominal surgeries are 
commonly done and have high rates of surgical site infections.
95,96,97Maksimović, J et 
al reported that orthopedic surgeries were more commonly associated with SSI.
98 
6.1. Prevalence of SSIs: 
           Among 2076, 134 patients showed local signs and symptoms and suspected to 
have postoperative wound infections.These caseswere evaluated and followed up. 
Among them culture was positive in 116(5.5%) cases and hence considered as cases 
of SSI in our hospital thus overall prevalence rate of SSIs was5.5%. Kumar  et al and 
Fahad et al reported SSIs as 2.5% , which is only half of our present study rate
99,100
. 
The current status of SSIs identified in their hospital concurs with the studies of 
SarojGoliaet al, Faizan Iqbal et al and Degnim et al who reported it as 4.3%, 5.4% and 
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7.3% respectively.
101,102,103
On the contrary, Setty NH et al and Emil Aga et al reported 
it as 21.66% and 22.2%
101,96
. The comparative studies of SSIs is given in table no.24. 
                           Table no.24: Prevalence of SSIs in different regions 
 
 
 
 
 
 
 
6.2. Gender wise distribution of SSIs:  
 The occurrence of SSIs were more in males (6.4%) as compared with females 
(4.1%) in the present study. A study by Hernandez et al (2005) conducted in a 
Peruvian Hospital reported more among males 65.6%
104
. Moses also reported male 
preponderance (64.3%) and this is in contrast to the study by Shanmugam et al who 
reported almost equal among females (52%) and males (48%).
105,106 
Increasing 
occurrence among males was attributable to nature of the infected wounds with which 
they come to surgical departments and also to more number of emergency among 
males. 
Studies done Year of Publication Prevalence 
Present study 2018 5.5% 
Kumar A et al 2017 2.5% 
Fahad A. et al 2014 2.55% 
SarojGolia 2017 4.3% 
Faizan Iqbal et al 2017 5.4% 
Degnim AC  2012 7.3% 
Setty NH et al 2014 21.66% 
Emil Aga 2006 22.2% 
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6.3. Age wise distribution in SSIs: 
 In the present study, distribution of SSIs among the age groups 25 and above 
was almost nearer to each other and varied from 4.9% to 6.7%. On the contrary, it was 
more among those below 25 and may be attributable to the nature of wound. In 
general, occurrence of SSIs was more as age advances since these cases were 
suffering from Diabetes mellitus and/or other co morbid conditions which contributes 
to decreased physiological defense mechanisms and poor immune function. It is 
supported by many studiesfor example Owens et al and Bharatnur et al who reported 
that more number of SSIs occurred among 36 to 50 years (1.3 times higher risk of 
acquiring SSIs than the ones who were in the age group of 10 to 35 years)
107,108
. 
Similarly, high rate of infection was noted in the later age groups by Mundhada AS et 
al.
109,
. 
6.4. Comparison of SSI in Elective vs Emergency surgeries: 
                 The present study includes 1820 elective surgeries and 256 emergency 
surgeries, and among them 94 (5.6%) and 22 (8.59%) developed SSI respectively. 
When the data was analyzed using 2/2 table it was noticed that the chances of 
development of SSIs were among emergency surgeries and odd‘s ratio was 0.57. The 
increased rate of SSI in emergency surgeries may be due to very narrow time span 
without proper patient preparation and surgical preparedness as well as contaminated 
wounds as in cases of road traffic accidents. The same has been citated in most of the 
studies done earlier on SSIs. Tabiri S et al also reported that emergency cases had 
higher number of SSIs (23.8%) as compared to elective cases (7.4%)
110,111
. In the 
69 
 
series of Dessie et al SSIs were reported in 61.7% emergency and 38.3% elective 
cases
112
. 
6.5. Distribution of SSI based on nature of wound: 
 Among 2076 patients, the number of clean, clean contaminated, contaminated 
and dirty surgeries were 1307, 519, 187 and 63 respectively. Dirty wounds (41.2%) 
had a higher rate of SSI followed by contaminated (11.2%), clean contaminated 
(5.2%) and clean (3.2%). These variations may be attributable to increased microbial 
load in the operative field which are of higher risk to SSIs. Similar to this study, 
Shrestha et al reported SSIs in2.9%, 15.3% and 18.7% of clean-contaminated, 
contaminated and dirty wounds respectively and none in clean wounds
113
. Dinda et al 
reported SSI rate as 5.5% for clean wounds, 8.8%, 20.1% and 29.9 % for clean-
contaminated, contaminated and dirty wounds respectively
114
. 
6.6. Type of SSI based on the extent of wound: 
 In the present study, superficial and deep SSI were 69(59.4%) and 47(40.5%) 
respectively.  Superficial SSI was found to be higher. Anusal kumar et al reported that 
superficial incision SSI was more prevalent (215 cases) 55.9% followed by deep 
incisional SSI (169 cases) 44% 
99
 and van Walraven et al reported the same with 
majority of these [n = 8188, 57.5% of all SSIs] had a superficial component115. This is 
discordant to the study by Dessie W et al who reported superficial SSI as 42.1% and 
deep SSI as 57.9%
112
. 
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6.7. Risk factors of SSI: 
1. Diabetes mellitus – In our study 64(55.1%) diabetic patients had SSI. Many 
published reports have demonstrated that patients with diabetes are more 
susceptible to wound infection because of impaired neutrophil chemotaxis and 
phagocytosis. The occurrence of SSIs among diabetes in the present study 
concurs with study of Lilienfeld e tal, Talbot et al
116,117
and Akter Z et al who 
reported SSI among diabetes was 50%. On the contrary, the occurrence of SSIs 
was very high (91.7%) among diabetic patients in the series of Korol et al
118,119
. 
2. Smoking – In our study 49 (42.2%) had Smoking habit. It has been shown to be 
an independent risk factor for SSIs
120,121
. Smoking delays the healing of SSIs 
by causing local and systemic vasoconstriction and impair tissue oxygenation. 
This results in tissue hypoxia, an environment conducive to SSI and an adverse 
effect on wound healing. Korol et al and Prakash et al reported SSI rate of 
63.2% and 66.7% respectively among smokers
119,122
. 
3. Alcoholism – In the present study 41(35.3%) of 116 SSIs were alcoholics. The 
present observations and the statement of Rantala et al were contradicted by 
Shabanzadeh et al who stated that alcohol did not affect SSIs and anastomotic 
leakage
123,124
. 
4. Prolonged postoperative hospitalization – In the present study 89 (76.7%) 
stayed for more than 7 days after procedure has been done. Anvikar et al. 
demonstrated that preoperative hospital stay predisposed an individual to 
1.76% risk of acquiring an infection
.125
Nichols RL et al says that prolonged 
postoperative hospitalization, which is a major concern of most of the 
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hospitals, has been evident in patients developing surgical site infection
126
.This 
is related to altered cellular immune function as a result of hyperglycaemia and 
advanced glycation end products which result in impaired healing. 
5. Anaemia contributed to 31(26.7%) cases of SSIs. Among these 16 received 
blood transfusion. It has been reported that perioperative transfusion of 
leukocyte-containing allogeneic blood components is an apparent risk factor 
for the development of postoperative bacterial infections, including SSI.
127
In 
three of five randomized trials conducted in patients undergoing elective colon 
resection for cancer, the risk of SSI was at least doubled in patients receiving 
blood transfusions.
128-130
.Watanabe reported that 58.8 % blood transfused 
patients develop SSIs. The occurrence of SSIs among those who receive blood 
transfusion was attributable to immune dysregulation. 
6. Drain – In our study with 116 SSIs, drain was kept only in 18(15.5%) 
cases.The use of surgical drains has been reported to be associated with the 
occurrence of SSIs
131,132
which was similar to Fujii et al who reported 14.3%. 
On the contrary, Cardosi et al reported SSIs in 22.4% who had drain
134
. 
7. ASA index- In our study, SSI incidence is higher in ASA III (n=59;50.8%) 
followed by ASA II(n=35 ;30.1%) and least in ASA I (n=16;13.7%).
48,49
 The 
occurrence of SSIs were significantly more in patients with ASA II to V than in 
those with ASA I, which is in agreement with many  studies,
135,136
 suggesting 
that the ASA score before surgery has a strong influence on the occurrence of 
SSI rates in clean and clean contaminated cases.Watanabe reported SSIs in 
ASA II (24.1%) and ASA III (55.0%)
137
. 
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6.8. Antibiotic prophylaxis – There is no standard guidelines for antibiotic 
prophylaxis for the surgeries. 3
rd
 generation cephalosporins and gentamycin were 
given to all 71(%) abdominal surgeries and 23(%) received 3
rd
 generation 
cephalosporins and metronidazole for pelvic surgeries. In thepresent study, 
prophylactic antibiotic was given to all 116 cases who had SSIs. Even though the 
patients received prophylactic antibiotics, they developed SSIs which may be due to 
differential pharmacokinetics of antibiotics, patient‘s own microbial load and other 
associated risk factors. Administration of a preoperative antibiotic did not decrease 
theoccurrence of SSI rate. Crawford CB et al noticed higher chances of occurrence of 
SSIs among those received prophylactic antibiotics. (12% SSI with antibiotics versus 
4% without, p < 0.0001)
138
. 
6.9. Distribution of various bacteria in SSIs: 
 In our study, out of 124 isolates from 116 patients, 35(28.2%) were gram 
positive cocci, 89(76.7%) were gram negative bacilli. Among gram negative bacilli, 
Enterobacteriaceae contributed 61(49%), (27(34.4%) E.coli, 19 (31.1%) Klebsiella 
spp, 7 (11.4%) Proteus mirabilis, 7(11.4%) Enterobacter spp and 1(1.6%) Citrobacter 
freundii). Non fermentor contributed 28(22.5%)(19 (15.3%) Pseudomonas aeruginosa 
and 9 (7.25%) Acinetobacter baumanii). In our study, Staphylococcus aureus 
32(25.8%) being the most common isolate followed by E.coli 27(21.7%), 19(15.3%) 
Klebsiella spp,19 (15.3%) Pseudomonas aeruginosa and 9 (7.25%) Acinetobacter 
baumanii and others. Our observations on higher isolation of Staphylococcus aureus 
(25.8%) tallied with Cantlon et al (2006) who also reported 26% of Staphylococcus 
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aureus. Rate of isolation of Staphylococcus aureus from SSIs in different series is 
shown in table no.25. 
Tableno.25: Comparative analysis of Staphylococcus aureus infection in SSIs
141 -143 
Study  Year of Publication Isolation of S.aureus 
1. Cooke et al  1979  30.3%  
2. Oni et al.  1997  38.0%  
3. Giacometti et al  2000  28.2%  
4. Onche and Adedeji 2004  44.0%  
5. Lilani et al  2005  56.3%  
6. Oni et al  2006  29.0%  
7. Cantlon et al 2006  25.8%  
8.Suchitra et al 2009 33.0% 
9. Shriyan et al  2010 63.0% 
10. Mistelia et al  2011 29.5% 
11. Present study 2017-18 25.8% 
 
 Though the Enterobacteriaceae was the second most frequently (49%) isolated 
organisms in the present study Cantlon et al noticed it to be low (12.4%).
139
 Similar to 
our study, rate of isolation of E.coli 28(44%), Klebsiella spp 21(31.2%) and 
Pseudomonas aeruginosa 19 (67%) by Arias et al was nearer to the present study
99
 
whereas Rao and Harsha (1975) observed P. aeruginosa, E. coli and Klebsiella spp. as 
the common gram-negative organisms. Also, Giacometti et al(2000) noticed 
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Pseudomonas aeruginosa (25.2%) to be the predominant organism in their study 
followed by Escherichia coli (7.8%) and others.
140 
 Surgical site infections caused by bacteria that are resistant to multiple classes 
of antimicrobials are an important and increasing problem.  Organisms such as 
methicillin-resistant staphylococci, extended spectrum beta-lactamase producing 
Enterobacteriaceae and multi-drug resistant Acinetobacter and Pseudomonas spp. are 
among the current concerns; however, the emergence and dissemination of other 
multi-drug resistant organisms is likely to follow. 
 Among 32 staphylococcus aureus, 11(37.9%) were MRSA identified using 
cefoxitin disc diffusion method  similar to the studies done by Ranjan (27.96%) 
144
, 
Krishna S (28.6%)
103
 and Farrin 29%.
145
 It is discordant with the study by Golia S et 
al who reported 88.8% of S. aureus as methicillin resistant strains
103
. 
 Sanjay et al (2010) in their study on isolation and detection of drug resistance 
gram negative bacilli with special reference to postoperative wound infection noticed 
that E. coli was the predominant agent isolated from wound infections (37.3%), 
followed by Pseudomonas aeruginosa (20.9%), Klebsiella spp (17.2%), Acinetobacter 
baumanii (14.2%) and other agents were less common
146
. 
 In the present study, none of the isolates Klebsiella spp, Proteus spp, 
Acinetobacter baumanii and Pseudomonas aeruginosa were sensitive to Ampicillin 
and Amoxyclav. E.coli and Enterobacter spp showed only 14.2% sensitivity to 
Amoxyclav.  The sensitivity of Acinetobacter baumanii for different antimicrobial 
agents commonly ranged from 11% to 55%. The sensitivity was high to Piperacillin-
tazobactam followed by Imepenem. In general, Acinetobacter baumanii was resistant 
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to fluoroquinolones, aminoglycosides, and all β-lactams, with the exception of the 
carbapenems and hence considered as the drug of choice.
147
 with regard to 
Acinetobacter spp. 
 Brown et al noticed high resistance rate to many antimicrobial including 
carbapenem and it is emerging in many parts of the world,
149
 mainly due to 
carbapenemases and  possibly other mechanisms, such as alterations of outer 
membrane proteins
148
 and these multiresistant Acinetobacter spp. may still retain 
susceptibility to the polymyxins (i.e., colistin and polymyxin B), sulbactam, and 
possibly tigecycline. Pan resistant isolates that are resistant to all available drugs are 
now being reported
150
. The prevalence of resistance is more in the Europe, America 
than in Asia/Pacific.  
6.11. Distribution of ESBL producing gram negative bacilli in SSIs: 
 In the present study, 28/61(46%) were ESBL producers on combined disc test. 
Organisms were 14(53.5%) were E.coli, 11(39.2%) were Klebsiella spp, 2(7.0%) were 
Enterobacter spp. This is not in concurrence to the study by Rambabu et al who 
showed a prevalence rate of 35.71% ESBL producers (E.coli – 56%, Klebsiella spp – 
52%, Proteus spp – 40% and Enterobacter spp – 16%). Asfia Sultan et al reported 
that 30% were ESBL. Prevalence of ESBL producers is high in a study by Golia et al 
who noticed 80% of E. coli and 100% of Klebsiella species 
151-153 
6.12. Distribution of Amp C producers in SSIs: 
 In the present study 15(16.8%) were Amp C producers by disc test. 6 were 
Pseudomonas aeruginosa, 4 Acinetobacter baumanii, 3 Klebsiella spp, 1 E.coli and 1 
Enterobacter spp. On the contrary, Hemalatha reported 9.2% Amp C producers which 
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was much lower than present study. Compared to ours Asfia Sultan et al and Tapan et 
al, reported very high prevalence (64.7%) and (48.5%) Amp C producers 
respectively.
154,152,153
. 
6.13. Distribution of MBL in SSIs: 
 In the present study 12(13.2%) were MBL producers. Among them were 
5/9Acinetobacter baumanii (41.6%), 4/19Pseudomonas aeruginosa (21%), 1/27 E.coli 
(8.3%) and 2/19 Klebsiella spp(16.6%). Similar to our study Gupta reported 40 % of 
A. baumannni and 20% of P.aeruginosa isolates showed resistance to imipenem
155,156
. 
6.14. Distribution of multidrug resistance in SSIs: 
 In the present study 44(35.4%) isolates were resistant to three or more group of 
drugs and these MDR organisms were Staphylococcus aureus 11 (25%), Klebsiella 
spp 9(20%), Pseudomonas aeruginosa 9(20%), E.coli 7 (15%), Acinetobacter 
baumanii 6(13.6%) and Proteus mirabilis 2(4.5%). In the series by Manyahiet al 63% 
(93/147) were multidrug resistant (MDR) whereas Zahran et al reported 37.2% of 
MDR isolates.
157,158
. 
               The present study has revealed the prevalence of SSIs in our centre. The 
SSIs were noticed more among the patients who underwent abdominal surgeries the 
highest rate in laparotomy. SSIs were frequent among those who had one or other risk 
factors. Bacteriological studies revealed SSIs were more due to gram negative bacilli. 
The present study indicates that every institution has to maintain a surveillance of 
SSIs and to find out changing trends so as to curtail SSIs and infections due to MDR 
strains. 
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7.0. SUMMARY 
                          This study entitled, “Bacteriological Profile, Antibiogram and Risk 
Factors of Surgical site Infections in a Tertiary care hospital”, was carried out in 
the department of Microbiology, Trichy SRM medical college hospital and research 
centre, Trichy from May 2017 to April 2018. 
 
 
 Over a period of 12 months (May 2017 – April 2018), a total of 2076 patient 
underwent various surgeries. Among them, 134 patients were suspected to have 
SSI from various departments. 124 pathogens were recovered from 116 
samples (8 were polymicrobial infections), the remaining 18 patients yielded 
no growth. 
 Prevalence of SSI in our hospital was 5.6%  
 Abdominal surgeries commonly lead to SSI especially laparotomy procedure 
(20/78; 25.6%) who had one or more risk factors. 
 Emergency surgeries (8.5%) pose higher infection rate than elective surgeries 
(5.1%). 
 SSI rate was high in dirty (41.2%) and contaminated wounds (11.2%) when 
compared to clean surgeries. 
 Male predominance was seen in present study. 
 71.7% gram negative bacilli and 28.2% gram positive cocci were isolated. In 
that, Staphylococcus aureus accounted for 25.8%of SSI followed by 
E.coli21.7%, Pseudomonas aeruginosa 15.3%, Klebsiella spp 15.3% and 
others. 
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 Out of 32 Staphylococcus aureus 11(38%) were Methicillin resistant 
Staphylococcus aureus(MRSA). 
 Gram negative bacilli which showed resistance to 3rd generation 
cephalosporins, cefoxitin and imepenem in routine antiobiotic susceptibility 
tests were subjected to phenotypic confirmatory test for ESBL, Amp C and 
MBL production. 
 Phenotypic tests were performed on the 81 gram negative bacilli namely 
combined disc test, Amp C disk test and Modified Hodge test which showed 
46%, 16.8% and 13.2% were ESBL, Amp C and MBL producers.  
 35.3% were MDR strains. 
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Suggestions:  
 
 As the study has brought out the occurrence of surgical site infections, it is time 
to decide and initiate regular surveillance of SSI on monthly basis and the same 
should be discussed in the Hospital Acquired Infection Control Committee meetings 
on departmental basis. 
                 Based on the reports, measures to prevent and reduce the rate of SSIs which 
also serve on quality indicators and surveillance markers of hospital acquired 
infections. 
                The documents related to SSI shall be kept as a valuable document to 
defend the hospital and the surgeons when they are questioned by administrative, 
social, accrediting and legal authorities. 
               The present study reveals the usage of prophylactic antibiotics alone will not 
prevent the development of SSIs, as occurrence of SSI is a complex interplay of host 
factors, factors related Healthcare workers and environmental factors. 
                The study also stresses the importance of formulation of antibiotic policy 
based on the prevalent bacteria and their antimicrobial sensitivity pattern. 
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8.0. CONCLUSION 
 
                    A total of 2076 patients underwent various surgeries including 
elective as well as emergency surgeries during consecutive 12 months 
commencing from May 2017 – April 2018. Standard methods were adopted to 
collect sociodemographic, clinical and microbiological data. SSIs were suspected 
in 134 patients. The clinical signs and symptoms started appearing from 4
th
 day 
onwards and more no of cases manifested features of infection either on 5
th
 or 6
th
 
postoperative day. 18 samples showed no growth and the remaining 116 samples 
yielded 124 isolates (8 were polymicrobial infections). 
                 The prevalence rate of SSI in our hospital during the study period was 
5.6%.The SSI were more common in abdominal surgeries highest being in 
laparotomy surgeries (20/78; 25.6%). The odd‘s ratio for the development of SSIs 
in emergency cases was 0.57 and among males was 1.61. All these cases had one 
or other risk factors also. 
                 The occurrence of SSIs was high in dirty (41.2%) and contaminated 
surgical wounds (11.2%) when compared to clean surgeries. Interestingly, SSIs 
were more among those belonging to age group 16-24 yrs (11.9%) and odd‘s ratio 
was 2.45. SSI was independent of prophylactic antibiotic administration. During 
the study period, SSIs developed in all patients who received prophylactic 
antibiotics thereby indicating that prophylactic antibiotics did not protect the 
individual from developing SSIs. 
                     Smear studies of 134 samples revealed pus cells in all but smear had 
bacterial agents in only 37. For practical purposes, SSIs have to be considered 
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essentially if patients had clinical signs and symptoms locally and systemically, 
provided sample reveal pus cells more than 20/oil immersion field. From 116 SSIs, 
124 isolates were obtained (monomicrobial – 108 and polymicrobial – 8). The 
isolates were gram positive which included Staphylococcus aureus (n=32) and 
Enterococci (n=3); and gram negative (n=89) which included Enterobacteriaceae 
(n=61) and non fermentors (n=28). 
               Among 32 Staphylococcus aureus, 11(38%) were Methicillin resistant 
Staphylococcus aureus. Gram negative bacilli which showed resistance to 3
rd
 
generation cephalosporins, cefoxitin and imepenem in routine antiobiotic 
susceptibility testing were subjected to phenotypic confirmatory test for ESBL, 
Amp C and MBL producers. Phenotypic test were performed on the 81 gram 
negative bacilli such as combined disc test, Amp C disk test and Modified Hodge 
test showed 46%, 16.8% and 13.2% of them were ESBL, Amp C and MBL 
producers. The prevalence of MDR strains during the study period was 35.3%. 
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Strengths of the study:  
 
 The isolation and confirmation was monitored by two faculty members and 
guide. 
 Phenotypic confirmatory test for ESBL, Amp C and MBL were done and it was 
more among general surgery cases. 
 The works were monitored by all senior independently.  
 Standard media and chemicals were purchased for lab works.   
 Clinical correlation when analyzed with regard to SSI, it was noticed more 
among Diabetes mellitus, elders and those received blood transfusion. 
Limitations of the study:  
 It is a single center study confined to aerobic bacterial pathogens. 
 Resistance genes of MDR strains were not considered during the study period. 
Future study: 
 Molecular epidemiology using genotypes of the isolates and its antimicrobial 
resistance is expected to reveal, geographic distribution of the resistant strains. 
 It is suggested to work on anaerobic organisms among those cases admitted for 
treatment of road traffic accidents and penetrating injuries requiring surgical 
intervention. 
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ANNEXURE -III
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ANNEXURE- II 
PROFORMA 
Date: 
1. Sl.no: 
2. Name: 
3. Age/Sex:  
4. IP no/Ward/Unit: 
5. Address: 
6. Occupation:  
7. Personal history smoker/ non smoker/ alcoholic/ non alcoholic 
8. Diagnosis: 
9. Risk factors: Blood glucose control in DM /existing infection/MRSA carrier/old 
age/obesity/ischaemia/ trauma/shock/hypothermia/hypoxia. 
10. Preoperative risk factors: chlorhexidine bath taken/not taken/hair removal by electric 
clipper/razor/cream/ no of preoperative hospital days  
11. Intraoperative risk factors: Duration of surgery/multiple assistance/experience of 
surgeon/tissue injury/blood transfusion. 
12. Type of surgery: 
13. Site of surgery: 
14. Duration of surgery: 
15. Cleaning & disinfection of OT: very good/good/fair 
16. Adherence to aseptic procedure: yes/no 
17. Prophylactic antibiotic: used/ not used 
18. If used, antibiotic prescribed/dose/duration/route of administration 
19. Educate the patient regarding incision care & SSI: yes/no 
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20. Local examination:redness/warmth/swelling/discharge 
21. Microbiological examination: 
22. Grams stain: 
 
 
 
 
 
23. Culture & sensitivity: 
 
 
 
 
 
 
 
 
 
24. Follow up: improved/ not improved 
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KEY WORDS TO MASTER CHART: 
RISK FACTORS- 1- DIABETES, 2- SMOKING, 3- ALCOHOLISM, 4- ANAEMIA, 5- BLOOD 
TRANSFUSION, 6-DRAIN, 7-HOSPITAL DAYS. 
TYPES OF SURGERY- C- CLEAN, CC- CLEAN CONTAMINATED, CO- CONTAMINATED, D- 
DIRTY. 
ORIF- OPEN REDUCTION AND INTERNAL FIXATION, TURP- TRANSURETHERAL 
RESECTION OF PROSTATE, LSCS- LOWER SEGMENT CAESAREAN SECTION, MRM- 
MASTOIDECTOMY,TONSIL- TONSILLECTOMTY, CSOM- MASTOIDECTOMY 
SUR- SURGERY, PA- PROPHYLACTIC ANTIBIOTICS, A- CEFOTAXIME, B- 
CEFTRIAXZONE, C- GENTAMYCIN, D- METRONIDAZOLE.  
ND- NOT DONE 
 
 
 
 
 
 
 
87 
 
SL.N
O 
AG
E 
SE
X 
IP 
NO 
WAR
D DIA/PRO 
RISK 
FACT
OR 
TYP
E 
P
A 
ORGANI
SM P 
D
O E 
C
D G 
A
K 
CI
P 
CO
T 
TE
T 
L
Z 
HL
G 
FOLLO
W UP   
1 47 F 
2479
27 SUR 
APPENDICIT
IS 
1,4,5,6,
7 CO A MRSA R S R R R S S R R S ND IMP   
2 35 M 
2482
24 SUR HERNIA 
1,2,3,7,
6 CO 
B
C MRSA R S S S R S S S S S ND IMP   
3 21 M 
2481
95 SUR 
APPENDICIT
IS 2,3 CO A MRSA R R R R S S R S S S ND IMP   
4 36 M 
1953
29 SUR HERNIA 2,3,6 CC 
B
C ENTERO R S S 
N
D 
N
D 
N
D R ND R S S IMP   
5 25 F 
2438
43 SUR CHOLECYST 6,7 CO A MRSA R S S S S R S S S S ND IMP   
6 67 F 
1387
45 
ORTH
O ORIF 1,4,6,7 CC 
A
C MSSA R S S S R S S S S S ND IMP   
7 37 M 
2464
14 SUR CHOLECYST 1,2,3,7 CO B MRSA R S S S S R S R R S ND IMP   
8 29 F 
2464
71 SUR APPENDIcits 4,5,7 CC A ENTERO R S S 
N
D 
N
D 
N
D S ND S S S IMP   
9 40 M 
2463
37 SUR HERNIA 
1,2,3,7,
6 CC 
B
C MSSA S S S S S R S S S S ND IMP   
10 52 M 
2470
46 SUR LAP 
1,2,3,7,
6 D 
C
A MSSA S S S S R R S S S S ND AMA   
11 47 F 
1394
02 SUR MRM 1,4,7 C A MRSA R S S S S S S S S S ND IMP   
12 41 M 
2494
11 SUR HERNIA 
1,2,3,6,
7 CC 
A
C MRSA R S S S R R S R R S ND 
ABSCO
ND   
13 47 M 
2276
83 SUR HERNIA 
1,2,3,7,
6 CC 
B
C MRSA R S S S R S S S S S ND IMP   
14 34 F 
1804
32 SUR MRM 4,5,7 C A MSSA S S S S S S S S S S ND IMP   
15 39 M 
2277
22 
ORTH
O ORIF 2,6 CC 
B
C MSSA R S S S R S S R S S ND DIED   
16 27 M 
2276
78 SUR FISTULA 2,6 CC D MSSA R S S S S S S R S S ND IMP   
17 48 F 
2464
84 SUR MRM 1,4,5 C B MRSA R S S R S S R S R S ND IMP   
18 44 M 2867 SUR LAP 1,2,3,6, D A ENTERO R R S N N N R ND R S S IMP   
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98 7 C D D D 
19 22 M 
2479
85 ENT CSOM 2,3 CC A MSSA R S R S R S S S S S ND IMP   
20 42 M 
2482
11 SUR APPENDIX 1,3,7,6 CC B MSSA R S S S S S S S S S ND IMP   
21 64 M 
2774
51 SUR 
HEAMORRH
OID 
1,2,3,6,
7 CC D MSSA R R S S S S S S S S ND IMP   
22 41 M 
2477
82 
ORTH
O ORIF 
1,2,3,7,
6 CC 
B
C MSSA R S S S S S S S S S ND IMP   
23 20 M 
2452
85 SUR APPENDIX 6,2 CC A MSSA R S S S S S S S S S ND 
ABSCO
ND   
24 61 M 
2449
10 
ORTH
O ORIF 1,2,3,7 C 
B
C MSSA R S S S S S S S S S ND AMA   
25 39 M 
2315
51 SUR CHOLECYST 2,3,6,7 CC B MSSA R R S S S S S S S S ND IMP   
26 57 M 
2305
52 
ORTH
O KNEE 1,2,3,6 CC 
B
C MSSA R S S S S S S S S S ND IMP   
27 21 M 
1382
05 ENT CSOM 2 C B MRSA R S R R R S R S R S ND IMP   
28 43 M 
2455
21 SUR HERNIA 1,2,3,7 CC 
B
C MSSA S S S S S S S S S S ND IMP   
29 29 M 
2656
77 ENT CSOM 7 C A MSSA R S S S S S S S S S ND IMP   
30 21 M 
2464
85 ENT CSOM 6,7 C A MRSA R R R R S R R S R S ND IMP   
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AGE SEX IP NO WARD PRO/DIA TYPE 
RISK 
FACTOR PA ORGANISM AMP AMC G  AK COT CIP CAZ CTR CTX AT IPM PIT CPM CX 
FOLLOW 
UP 
17 M 143359 ENT MASTOIDECTOMY C 7,6 B PSEUDO R R S S S S S N N S S S S S IMP 
59 M 245927 SUR FISTULECTOMY CC 1,7,6 DA E.COLI S S S S S S R S S S S S S S IMP 
38 M 247239 SUR SPHINCTER CC 2,3, DA E.COLI R S S S S S S S S S S S S S IMP 
65 M 247226 SUR HERNIOPLASTY CC 1,2,7,6 A PSEUDO R R S S S S S N N S S S S S IMP 
63 F 247707 SUR LAPAROTOMY D 1,7,6 AC PSEUDO R R S R S S S N N S S S S S IMP 
37 F 237740 SUR CHOLECYSTEC D 4,5,7,6 B ACINETO R R S R S S S R S S S S R S IMP 
61 M 251474 SUR LAPAROTOMY D 1,7,6 AC E.COLI R R S R R R R S R R R R R R IMP 
56 M 252174 SUR LAPAROTOMY D 1,2,3 AC KLEB R R S R S S S S R S S S S S IMP 
54 M 252174 SUR APPEN CC 1,7,6 A E.COLI R S R S S S S R R S S S S S IMP 
41 M 252088 SUR LAP D 7,6 A KLEB R R S R S R S S S S S S S S IMP 
57 F 246929 SUR HERNIA CC 1,4,5,7,6 AC ACINETO R R R S S S R S S S S S S S IMP 
51 M 272088 SUR APPENDIX C 1,2,3 B E.COLI R S S S S S S R S S S S R R DIED 
59 F 246929 SUR LAP D 1,4,5,7,6 BC KLEB R R S R S R S S S S S S S S AMA 
43 M 296946 SUR LAP D 1,2,3 B E.COLI R R S S S S S R R S S S S S IMP 
31 F 252586 SUR APPENDIX CC 4,5,7,6 B KLEB R R S R S S R R S S S S S S IMP 
55 M 251335 SUR HAEMOR CC 1,2,3,7,6 D KLEB R R S R R R S S S S S S S S IMP 
29 M 251367 SUR CHOLECYST CO 7,6 A CITRO R R R S S S S S S S S S S S IMP 
61 F 252605 SUR CHOLECYST CO 1,7,6 A E.COLI R R S S S S S S S S S S S S IMP 
51 M 252437 SUR HERNIA CC 1,2,3,7 B PROTEUS R R S S S R R S R S R S R S IMP 
21 F 282437 OG LSCS CC 4,5,7,6 BC E.COLI R R S S S S S S S S S S S S IMP 
39 M 292883 SUR HAEMORRHOID C 6,7 D KLEB R R S S S R S R S S S S S S IMP 
48 F 252066 OG HYSTER CC 1,4,5,7,6 A KLEB R R S S R S S S R S R S S R AMA 
68 M 252142 SUR LAPROTOMY D 1,7,6 AC E.COLI R R S S S S R S S S S S S S IMP 
71 F 259913 ORTHO HIP C 6,7 B KLEB R R S S S S S S R S S S S S DIED 
32 F 233483 OG LSCS CC 6,7 AC PROTEUS R R S S S S S S S S S S S S IMP 
55 M 252066 SUR HERNIA CC 1,2,3 B E.COLI R R S S S S S S S S S S S S IMP 
63 F 253483 SUR HERNIA C 1,4,7,6 B KLEB R R S S R S S S S S S S S S IMP 
51 F 252064 OG LSCS C 1,4,7,6 BC E.COLI R R R R R R R R R R R R R R IMP 
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29 M 249913 SUR FISTULA C 2,3 D PSEUDO R R S R R S S N N S S S R S IMP 
46 M 249712 SUR APPENDIX CO 6,7 A ACINETO R R R S R R S R R R S S R S IMP 
64 F 253403 ORTHO KNEE CO 1,4,5,7,6 B E.COLI R R S S S S S S R S S S S S IMP 
56 M 242742 SUR FISSURE C 1,2,3,7,6 D ACINETO R R R R R R R R R R R R R R IMP 
30 F 150832 OG LSCS C 6,7 BC KLEB R R S S R S R R R S S S S S IMP 
54 M 253198 SUR LAPROTOMY D 1,2,3,7,6 CA KLEB R R R S R R R R R S S S S S IMP 
46 F 231837 SUR CHOLECYST C 4,5,7,6 B E.COLI R R S S S S S R S S S S S S IMP 
21 M 251830 SUR APPENDIX CO 2, B ACINETO R R R R R R R R R R R S R R IMP 
33 F 253057 OG LSCS C 4,7,6 BC PROTEUS R R S S S S S S S S S S S S IMP 
58 M 253415 SUR LAPROTOMY D 1,7,6 AC E.COLI R R S S S S S S S S S S S S IMP 
31 F 257045 SUR HAEMORRHOID C 2,3,7,6 D PSEUDO R R R S R S S N N S S S S S AMA 
69 M 256719 SUR LAPRO D 1,7,6 B E.COLI R R S S R R R S R R S S S S IMP 
28 F 255736 OG LSCS C 6,7 AC PSEUDO R R S R S S S N N S S S S R IMP 
19 M 256436 ENT TONSIL C 6,7 A PROTEUS R R S S R S S S S S S S S S IMP 
53 M 255585 SUR CHOLECYST CO 1,2,3,7,6 A PSEUDO R R R R R R S N N S S S S R IMP 
66 M 254818 SUR HERNIA C 1,7,6 A E.COLI R R S S S R S R S S S S S S IMP 
36 M 256028 SUR APPENDIX   2,3,7 B PROTEUS R R R S S S S S S S S S S S AMA 
27 M 256221 SUR LAPRO CO 2, AC KLEB R R R S R R R R R S S S R R IMP 
65 M 254303 SUR LAPRO CO 1,2,3 AC PSEUDO R R R R R S S N N R S S S S IMP 
37 M 255605 ORTHO ORIF C 2, AC KLEB R R R S R R R R   S S S R S ABSCOND 
39 M 256453 SUR APPENDIX CO 2,3,7 A E.COLI R R S S S S R S R S S S S S AMA 
68 F 186192 SUR LAPROTOMY D 1,7 AC PSEUDO R R S R R R R N N S S R S R IMP 
51 F 186240 OG LSCS C 1,7 A PSEUDO R R R S R R S N N R S R S R IMP 
28 F 258083 ORTHO 0RIF CO 4,5 BC PSEUDO R R S R R R R N N S S R S R IMP 
71 M 258858 SUR HERNIA CO 1,7 BC E.COLI R R S S R R S R S S S S S S IMP 
34 M 257126 ORTHO ORIF C 2, BC PSEUDO R R R S R R S N N R R S R S IMP 
51 M 257341 SUR LAPROTOMY D 1,2,3 B ENTEROBACTER S S S S R S S R S S S S S S IMP 
65 M 257221 SUR LAPROTOMY D 1,7 BC ENTEROBACTER R R S S S S S S S S S S S S IMP 
37 M 257984 ORTHO ORIF D 2, BC PROTEUS R R R R S S S S S R S S S S IMP 
48 F 258100 ORTHO HIP C 1,7 A PSEUDO R R R R S R S N N S S S S S IMP 
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24 F 258099 OG LSCS C 4,5,7 BC ENTEROBACTER R R S R S S R S R R S S S R IMP 
67 M 254862 UROLOGY TURP C 1,7 D PSEUDO R R R S R R S N N R S S S S IMP 
44 M 251066 SUR HERNIA CO 2, AC E.COLI R R S S R R R R R S S S R S IMP 
38 F 257860 ORTHO HIP C 7, BC ACINETO R R R R R R R R R R R S R R IMP 
58 M 257673 SUR CHOLECYST CO 1,7 A E.COLI R R S S R R R R R S S S R S IMP 
38 M 257636 SUR HERNIA CO 2,3 BC KLEB R R R S R R R R R S S S R S IMP 
33 M 258089 ORTHO ORIF D 2,3 B PROTEUS R R R R R R S R R R S R S R IMP 
56 M 257677 SUR HERNIA C 1,7 B ENTEROBACTER R R R S S S S S S S S S S S AMA 
49 M 257462 UROLOGY TURP C 1,2,3 A PSEUDO R R R S R R R N N R S S R R IMP 
39 F 255696 ORTHO ORIF D 5,7 BC E.COLI R R R S R R R R R S S S S S DIED 
16 M 256781 ENT TONSILECTOMY C 7 A ACINETO R R R R R R R R R R R R R R IMP 
60 M 256397 SUR HERNIA C 1,7 B E.COLI R R R S R R R R R S S S R S ABSCOND 
41 M 256931 SUR CHOLECYST CO 1,2,3 A PSEUDO R R R R R R R N N R S S R S IMP 
61 M 256138 ORTHO HIP REPLACE D 1,7 BC KLEB R R R S R R R R R R S S R S IMP 
40 M 247014 SUR LAPROTOMY D 1,2,3,7 BC PSEUDO R R S S R R R N N S R S R S IMP 
53 M 248919 ORTHO HIP REPL C 1, A E.COLI R R R R R R R R R R R S R R IMP 
45 M 244826 SUR LAPROTOMY C 1,2,3,7 BC ENTEROBACTER R R S S S S R R S S S R S S IMP 
57 M 819666 ORTHO KNEE FRAC D 1,7 AC KLEB R R R S R R R R R R S S R S IMP 
53 M 231522 SUR CHOLECYST C 1,2,7 B E.COLI R R R R R R R R R S S S R S IMP 
43 M 231987 ORTHO ORIF D 7 AC ACINETO R R R R R R R R R R R R R R IMP 
22 M 249187 ENT CSOM C 6,7 A PSEUDO R R R S R R R N N S R S R S IMP 
51 M 232193 SUR CHOLECYST C 1,7 B PSEUDO R R S R S R R N N S R S R S IMP 
43 M 249235 ORTHO ORIF C 6,7 BC E.COLI R R R R R R R R R S S S R S IMP 
47 M 249504 SUR APPENDIX C 6,7 B ENTEROBACTER R R S S R R S S R S S S S S ABSCOND 
39 M 232690 SUR LAPRO D 6,7 BC ENTEROBACTER R R S S R R S R R R S R R R AMA 
58 M 297739 ORTHO KNEE FRAC D 1,3,7 A E.COLI R R R S R S R R R S S S R R IMP 
51 M 249756 ORTHO 0RIF C 1,3,7 AC KLEB R R R S R R R R R R R S R R IMP 
59 F 248417 ORTHO HIP REPLACE D 5,7 BC E.COLI R R R R R R R R R S S S R R ABSCOND 
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